EP0651663B1 - Verfahren für nadellose subkutaninjektionen - Google Patents

Verfahren für nadellose subkutaninjektionen Download PDF

Info

Publication number
EP0651663B1
EP0651663B1 EP93918344A EP93918344A EP0651663B1 EP 0651663 B1 EP0651663 B1 EP 0651663B1 EP 93918344 A EP93918344 A EP 93918344A EP 93918344 A EP93918344 A EP 93918344A EP 0651663 B1 EP0651663 B1 EP 0651663B1
Authority
EP
European Patent Office
Prior art keywords
ampule
valve
pressure
poppet
reservoir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP93918344A
Other languages
English (en)
French (fr)
Other versions
EP0651663A4 (de
EP0651663A1 (de
Inventor
Steven Fisher Peterson
Charles Neal Mckinnon, Jr.
Paul Edward Smith
Takaaki Nakagawa
Victor Leon Bartholomew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioject Inc
Original Assignee
Bioject Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioject Inc filed Critical Bioject Inc
Publication of EP0651663A1 publication Critical patent/EP0651663A1/de
Publication of EP0651663A4 publication Critical patent/EP0651663A4/de
Application granted granted Critical
Publication of EP0651663B1 publication Critical patent/EP0651663B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
    • A61M2005/31516—Piston or piston-rod constructions, e.g. connection of piston with piston-rod reducing dead-space in the syringe barrel after delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M5/2053—Media being expelled from injector by pressurised fluid or vacuum

Definitions

  • the present invention relates to a needleless hypodermic injection method.
  • Various needleless hypodermic injection devices have been known and used in the past for performing the method according to the invention. These devices, also known as jet injectors, typically use spring or compressed gas driven plungers to accelerate an injectant to a velocity sufficient to pierce through the skin and enter the underlying tissues.
  • US-A-4722728 discloses an injector which pressurizes a fluid injectant within an ampule by driving a plunger into the ampule with sufficient force to expel the desired volume of fluid.
  • Jet injection avoids or diminishes these disadvantages.
  • the characteristics of needleless or jet injections typically vary with the pressures exerted by the injection device, the nozzle diameter of the ampule, the patient's size, age and weight, the nature of the injection site, and the viscosity of the injectant.
  • a long standing basic difficulty with jet injection has been the complex problem of determining which are the preferred injection variables. These variables include: 1) pressure profile, 2) nozzle size, 3) patient factors, i.e., age, sex and size, 4) injection site, and 5) medication viscosity.
  • the repeated failures of the prior art to adequately solve these complex variables problems has contributed to the lack of acceptance of a handheld and portable jet injector in the medical community.
  • the pressure profile is the pressure exerted on the liquid injectant, typically measured over time, from the beginning to the end of the injection.
  • the pressure profile must be selected, in combination with the nozzle size and other factors, to deliver the injectant through the skin to the desired depth, preferably with minimum pain.
  • the patient factors are also important. Gender is significant as women typically have a different adipose distribution than men. Men also typically have tougher tissue that women. The patient's age is important because infants are born with very little muscle, thick layers of adipose, and very easily penetrated skin. As infants age and become mobile the adipose is gradually replaced by muscle. At adolescence the introduction of hormones changes tissue composition. Aging through mid-life is usually associated with gradual weight gain and decrease in tissue strength.
  • Injection sites are very significant because in all patients the thickness of the skin and adipose tissue varies at different regions of the body.
  • the medical profession has established generally accepted injection sites for conventional needle syringes that are best suited for specific types of injection.
  • the subcutaneous sites typically have a thick adipose layer and are free of major nerves and vasculature.
  • Intramuscular sites typically have a thin adipose layer, a thick muscle layer, and are free of major nerves and vasculature.
  • the viscosity of the injectant must be considered as it effects characteristics of the jet injection.
  • viscosity effects have been widely misunderstood in the prior art.
  • jet injection despite its great potential advantages, remains virtually unused. Accordingly, it is an object of the invention to provide an improved method for needleless injection, so That the advantages of jet injection may be brought into use.
  • the pressure profiles of the injectant, nozzle diameter, patient and injection site parameters, as well as injectant viscosity, are selected to achieve desired injection characteristics.
  • the injectant is purposely deposited on the deep fascia in a thin sheet. This provides rapid absorption into the blood stream, without the invasiveness, injection discomfort, and occasional post injection soreness associated with injection deep into the muscle.
  • an injector or needleless injection device 20 which performs the method of the present invention has a front end 22 , a back end 24 , a top surface 26 and a bottom surface 28 .
  • a trigger 30 is slidably mounted on the injector 20 adjacent the bottom surface 28 .
  • the injector 20 includes an upper housing 42 and a shorter lower housing 44 attached to the upper housing 42 .
  • the lower housing 44 has a flat upper surface 82 which lies against a flat lower surface 84 of the upper housing 42 .
  • the upper housing 42 and lower housing 44 are attached together with four (4) pins 86 .
  • the upper housing 42 and lower housing 44 together are sized and shaped to readily fit the user's hand, with the user's palm resting over the top surface 26 and side of the injector 20 , and with the user's index finger easily positionable over the trigger 30 .
  • the top surface 26 has a step or incline 34 at approximately the center of the injector 20 .
  • the upper and lower housings may alternatively be formed as a single housing.
  • the lower housing 44 is substantially hollow and defines a lower housing space 48 .
  • the upper housing 42 defines an upper housing space 46 (Fig. 6).
  • a cartridge chamber 50 for receiving and holding a compressed gas cartridge 54 , e.g., a CO 2 cartridge.
  • a cartridge seat 52 at the forward end of the cartridge chamber 50 supports the back of the cartridge 54 .
  • a generally u-shaped plastic cartridge chamber cover 56 snaps into place on the lower housing 44 over the cartridge chamber 50 .
  • a generally cylindrical piercing housing 58 is slidably positioned behind the cartridge chamber 50 within the lower housing 44 .
  • O-rings 60 seal the piercing housing 58 against the lower housing 44 while allowing the piercing housing 58 to slide within the lower housing 44 .
  • An annulus 62 extends around the circumference of the piercing housing 58 in between the o-rings 60 .
  • a cylindrical piercing body 66 is positioned within the piercing housing 58 and sealed against the piercing housing 58 by o-rings 88 .
  • a piercing point 68 extends forward from the front surface of the piercing body 66 and is centrally aligned with the neck of the cartridge 54 .
  • a seal 64 on the front end of the piercing body 66 surrounds the piercing point 68 . The seal 64 extends sufficiently forward to seal against the neck of the cartridge 54 before the piercing point 68 penetrates into the cartridge 54 .
  • a bore 70 extends through the piercing point 68 and piercing body 66 connecting to the annulus 62 .
  • a piercing body nut 74 threads into the back end of the piercing housing 58 , to secure the piercing body 66 and seal 64 in position within and against the forward end of the piercing housing 58 .
  • a piercing housing nut 76 threads into the back of the lower housing 44 . Spanner tool openings are provided in the piercing body nut 74 and the piercing housing nut 76 for assembly purposes.
  • a threaded shaft 72 extends through and engages threads in the piercing housing nut 76 .
  • a knob 78 attached to the threaded shaft 72 has a flip handle 80 which can be flipped up perpendicular to the plane of the knob 78 to allow the knob 78 and threaded shaft 72 to be more easily tuned by hand.
  • the forward end of the Threaded shaft 72 bears against the back surface of the piercing body 66 .
  • a hole 92 extends through the upper surface 82 of the lower housing to connect the annulus 62 to a bore 96 leading into the upper housing space 46 .
  • An o-ring 94 seals the connection of the hole 92 and bore 96 .
  • a transparent window lens 98 secured to an end nut 108 by a rubber window retainer 100 .
  • a Bourdon tube 116 is soldered into a gauge base 114 and has an open end 124 extending into a gauge chamber 122 .
  • the pointer 102 extends perpendicularly from the back end of the Bourdon tube 116 .
  • a gauge label 104 applied to the back end of a gauge body 106 around the Bourdon tube 116 provides a calibrated pressure scale with the scale and pointer visible through the lens 98 . Stop pins extending from the back end of the gauge body 106 provide high and low pressure end point stops for the pointer 102 .
  • the end nut 108 has threads 110 at its forward end which engage the upper housing 42 .
  • the gauge body 106 is rotated relative to the gauge base 114 .
  • the gauge body 106 and gauge base 114 are adhered together.
  • a guiding pin 112 extends from the upper housing 42 into a keyway groove and holds the gauge body 106 in place while the end nut 108 is tightened.
  • Shims 118 are provided at the front surface at the gauge base 114 , as required, for proper stack up and positioning of components in the upper housing 42 .
  • An initiator valve housing 142 is spaced apart from the gauge base 114 by a filter retainer ring 120 .
  • a sandwiched assembly of filter disks 130 and synthetic filters 132 are contained within the back end of the housing 142 .
  • O-rings 140 seal the filter disks 130 against the retainer 140 and synthetic filter 132 .
  • O-ring 126 seals the filter retainer 140 within the upper housing 42.
  • O-ring 126 and o-ring 150 seal the gauge chamber 122 such that compressed gas provided Through the bore 96 can flow out of the gauge chamber 122 only through the filters.
  • a port 148 extends through the back wall of the initiator valve housing 142 into an initiator valve chamber 146 within the housing 142 .
  • An initiator valve 144 within the initiator valve chamber 146 controls gas flow from the port 148 through the initiator valve chamber 146 to a reservoir port 154 formed through the forward wall of the initiator valve housing 142 .
  • a regulation valve 156 includes a regulation seat 158 formed around the reservoir port 154 .
  • a dart 160 moves into and out of the regulation seat 158 .
  • the dart 160 has a threaded dart shaft 162 Threaded into the narrower tube section at the back end of a poppet body 172 .
  • a dart pin 164 extending through the tube section of the poppet body 172 and the threaded dart shaft 162 secures the adjustment of the longitudinal position of the dart 160 in relation to the regulation seat 158 .
  • a reservoir spacer 166 within the upper housing 42 extends from the forward end of the initiator valve housing 142 to a poppet housing 178 , forming a reservoir 168 around the tube section of the poppet body 172 .
  • O-rings 126 seal the reservoir spacer 166 against the upper housing 42 and seal the initiator valve housing 142 to the reservoir spacer 166 .
  • a poppet valve 170 within the poppet housing 178 has a conical plastic poppet seat 188 centered within and positioned against a forward wall of the poppet housing 178 .
  • the poppet body 172 has a sharp sealing edge 200 biased against the poppet seat 188 by a compression spring 186 held in position within the poppet housing 178 by a poppet nut 180 .
  • the sealing edge 200 and poppet seat 188 may be configured with unlike angles selected so that the inner diameter contacts first, to minimize creep effects.
  • the poppet nut 180 has a threaded forward section 184 engaged to a threaded rear section 182 of the poppet housing 178 .
  • the poppet nut 180 is tuned to adjust the compression on the spring 186 and correspondingly set the cracking pressure of the poppet valve 170 .
  • the diameter of the poppet seat 188 exposed to reservoir pressure prior to crack remains constant although the conical seat may creep, as the sealing surface, facing reservoir pressure, is parallel to the axis of poppet movement.
  • the conical seat is attached to the poppet housing 178 rather than the poppet body 172 while all hard (poppet) parts are made concentric and perpendicular.
  • all hard (poppet) parts are made concentric and perpendicular.
  • irregularities in the seat 188 or soft part will creep to conform to hard parts.
  • the hard parts are free to rotate but will still conform to the existing soft part deformation.
  • the seal 206 used with the back up ring 204 may be a low friction seal.
  • this seal is pressurized only after cracking due to the poppet body being pressurized internally before cracking, seal friction is greatly minimized.
  • the poppet body begins to move during opening before this seal is pressurized. Thus, breakway friction is not increased by gas pressure.
  • the poppet and regulation valves can act as a low pressure regulator.
  • a cannula 176 is attached to and extends back from a drive piston 212 in front of the poppet valve 170 through the poppet housing 178 and poppet seat 188 and into the back section of the poppet body 172 .
  • Poppet body supply holes 174 extend through the poppet body 172 (Fig. 3).
  • a cannula exhaust hole is provided through the cannula 176 at a position just slightly behind the o-ring 207 which slidably seals the cannula 176 .
  • radially spaced apart drive bores 194 extend through the poppet housing 178 and connect a poppet annulus 198 to the front surface of the poppet housing 178 .
  • the poppet annulus 198 a ring-shaped space, is formed by the inside walls of the poppet housing 178 , the front surface of the poppet 172 and the conical surface of the poppet seat 188 .
  • the front ends of the drive bores 194 are sealed by a preferably rubber disk drive bore seal 196 adhered to the back surface of the drive piston 212 .
  • a joggle 192 in the poppet housing 178 which engages a corresponding lip within the upper housing 42 , acts as a stop for the poppet housing 178 .
  • the reservoir spacer 166 , initiator valve housing 142 , filter ring, shims and the gauge body 106 are then subsequently installed within the upper housing 42 and stack up against the poppet housing 178 , with the end nut 108 clamping these components in place.
  • o-rings 206 slidably seal the poppet body 172 against the poppet housing 178 and poppet nut 180 .
  • the o-rings 206 and back up rings 204 prevent metal to metal contact during movement of the poppet body 172 and also act as pivots and guides to allow slight eccentricity between the poppet body 172 and poppet nut 180 .
  • a ring-shaped plenum 202 is formed between the poppet housing 178 and the drive piston 212 , or the o-ring 214 which slidably seals the drive piston 212 Within the upper housing 42 .
  • the plenum 202 is just wide enough to insure compression on the face seal 195 .
  • a backup ring 218 is provided adjacent to the drive piston seal 214 which is preferably a low friction U-seal.
  • a clap piston 210 is slidably positioned within the drive piston 212 and slidably seals against the drive piston 212 with a clamp piston o-ring 222 .
  • the back surface of the clamp piston 210 and the front vertical wall of the drive piston 212 form a clamp piston plenum 216 (Fig. 3).
  • An o-ring joggle 220 adjacent the back end of the drive piston 212 acts as a stop for the clamp piston o-ring 222 .
  • a clap piston spring 224 within the clamp piston 210 biases forward a jaw plate 228 butting against two opposing flange walls 229 (shown in phantom in Fig. 4) extending from a jaw retainer nut 242 , allowing just enough clearance for the jaws to move freely.
  • the force of the clamp piston spring 224 is accordingly transferred from the plate 228 to the flange walls 229 to the jaw retainer nut 242 and bypasses the clamp jaws 236 .
  • the clamp jaws 236 are biased outwardly or apart and away from each other by a pair of spaced apart jaw springs 238 .
  • the clamp jaws 236 have fine teeth 240 .
  • Each clamp jaw 236 has a planar ramp surface 234 flatly engaged by a corresponding planar ramp drive surface 232 on the forward end of the clamp piston 210 .
  • the jaw retainer nut 242 is threaded into the front end of the drive piston 212 .
  • a return spring 244 is compressed in between the jaw retainer nut 242 and a pressure plate 248 .
  • An indicator ring 250 is rotatably positioned in between the front end of the upper housing 42 and a front collar 252 threaded onto the front end of the upper housing 42 .
  • the indicator ring 250 has colored sections on its outside edge visible through view ports 256 in the front collar 252 , when the indicator ring 250 is turned to a ready to actuate position signifying that the ampule lugs are fully engaged with the injector lugs,
  • a detent pin 288 biased against the back surface of the indicator ring 250 holds the indicator ring in either the ampule loading/unloading position or the ready position, and provides a positive tactile (and optionally an audible click) indication that the ampule is correctly and fully installed, Referring to Fig. 13a, the detent pin 288 slides in or slides against a track 324 cut into the back of the indicator ring.
  • the return spring 244 biases the pressure plate 248 forward, to clamp an ampule behind the lugs 254 on the front collar 252 , and it also acts to return the drive piston after an injection.
  • the indicator ring 250 has three equally spaced apart tuning lugs 258 extending inwardly, for engaging the lugs 382 at the back of an ampule 360 (Fig. 10).
  • the front collar 252 has three equally spaced apart retaining lugs 254 extending radially inwardly, for engaging the front surfaces of the ampule lugs 382 , to hold the ampule into the injector 20 .
  • an actuator link 262 has a forward hook 264 in front of the indicator ring 250 .
  • a rear hook 260 on the actuator link 262 is attached to an actuator slide block 266 slidably mounted in between the upper housing 42 and lower housing 44 .
  • a slide block spring 268 pushing off of the lower housing 44 forwardly biases the actuator slide block 266 .
  • the forward surface of the actuator slide block 266 forms the trigger 30 .
  • an exhaust valve fork 270 extends laterally and upwardly from the actuator slide block 266 to engage a collar on a spool valve 286 .
  • the slide block 266 has a rounded back end 272 facing an initiator valve cam 274 pivotally attached to a holder with a roll pivot pin 278 . Together they are held in a cavity in the upper housing by the upper surface of the lower housing.
  • a gap 280 separates the rounded slide block end 272 and the initiator valve cam 274 (Fig. 3).
  • a set screw 276 threaded into the initiator valve cam 274 engages an initiator pin in the initiator valve 144 .
  • an orifice 282 in the upper housing 42 connects to a drive plenum exhaust bore 284 to continuously vent or bleed the drive plenum 202 to ambient pressure.
  • the orifice has an approximately 0.10 mm diameter opening.
  • the spool valve 286 attached to the exhaust valve fork 270 is slidably positioned within a spool housing 294 secured within an exhaust passage 296 in the upper housing 42 .
  • the spool valve 286 fits within a spool bore 302 in the spool housing 294 with a very close tolerance. While the spool valve 286 does not absolutely seal against the spool bore 302 , leakage between them is very low.
  • a reservoir exhaust bore 290 links the reservoir 168 to a spool valve plenum 300 around the spool valve 286 .
  • a spool valve hole 301 leads from the spool valve plenum 300 to an exhaust duct 304 behind the spool valve 286 .
  • O-rings 292 are positioned on either side of the spool valve plenum 300 to seal the stationary spool valve housing 294 around the reservoir exhaust bore 290 .
  • Muffler seals 306 seal the forward end of the spool valve housing 294 against a muffler tube 308 filled with fiberglass wool 310 or other acoustic material and leading to an exhaust port 316 open to ambient pressure.
  • a muffler retainer 312 and set screw 314 secure the spool valve housing 294 , muffler seals 306 and muffler tube 308 within the exhaust passage 296 .
  • the initiator valve 144 has an initiator valve pin 330 extending from a pin socket 332 .
  • a socket spring 334 overlying the pin socket 332 biases the initiator valve pin 330 outwardly or downwardly into engagement with the set screw 276 in the initiator valve cam 274 .
  • a valve stem 336 spaced slightly apart from the pin socket 332 has a stem collar 342 with a rubber seat ring 340 sealably engaging a seat neck 350 , within an upper chamber 344 of the initiator valve 144 .
  • a stem collar spring 346 positioned in between a valve nut 348 and the stem collar 342 biases the seat ring 340 into engagement with the seat nut 350 to maintain the valve 144 in a closed position.
  • the seat nut 350 is supported by, or part of a valve seat 352 sealed within the initiator valve chamber 146 by an o-ring 338 .
  • the housing is a single piece housing 303 , rather than the two-piece housing shown in Fig. 2.
  • FIG. 6b An alternative preferred design to the exhaust valve shown in Fig. 6 is illustrated in Fig. 6b wherein a valve stem 291 slides inside of a front seal 293 and a rear seal 295 .
  • a seal spacer 297 separates the front seal 293 and the rear seal 295 .
  • the rear end of the valve stem 291 has two narrow slots 305 which provide a channel for flow of gas when the valve is opened, while giving support to the pressurized rear seal 295 to prevent it from collapsing inwardly,
  • the slots 305 form a gradual angle with the rear seal 295 to prevent it from catching on an abrupt edge which could damage the seal.
  • valve stem 291 When actuated, the valve stem 291 is pushed forward and the front edge of the valve slots 305 moves forward to the forward edge of the rear seal 295 .
  • This allows pressurized exhaust gas to flow from an inlet port 307 , through the seal spacer 297 , out of the valve slots 305 , through a muffler 309 and into an outlet port 311 .
  • the front and rear seals 293 and 295 are both u-cup type seals to provide for low friction.
  • the exhaust valve is virtually gas tight and requires very little force for actuation. The only significant force that is translated to the valve stem is after opening, the stem is forced to open further which assists in returning the actuator of the injector.
  • Fig. 6c shows a piston plenum shut-off valve 321 used in the housing 303 , as an alternative to the continuously venting orifice 282 and drive plenum exhaust bore 284 shown in Fig. 6.
  • Shut-off valve 321 includes a piston 323 which has a filter 325 , an orifice 327 and a seal 329 .
  • the piston 323 is biased upwardly and into an open position via a spring 331 .
  • the force keeping the piston 323 down against the seal is provided by the pressure acting on the area of the annulus created by the piston seal 329 and the shut-off seal 333 .
  • the shut-off seal 333 is supported by a valve base 335 which has a vent 337 beneath the shut-off seal 333 to prevent seal escape. Passageways 339 are provided for venting gas.
  • the pressure acting on the valve is reduced, the piston 323 moves away from the shut-off seal 333 due to force provided by a spring 331 , and gas flows freely through the filter 325 , the orifice 327 , and through the passages 339 in the valve base 335 .
  • Figs. 7a and 7b show an alternate preferred embodiment initiator valve 145 (illustrated in the closed position).
  • the initiator valve 145 includes an initiator valve body 147 having an inlet 149 and an outlet 151 .
  • a valve poppet 153 is biased against a valve seat 155 by a spring 157 .
  • the valve seat 155 is preferably ethylene-propylene which resists absorption by carbon dioxide.
  • a valve seat retainer 159 supports the valve seat 155 .
  • a valve stem 169 passes through a valve stem guide 161 and a valve stem seal 163 .
  • a valve stem spring 165 biases the valve stem into a closed position.
  • a valve stem seal 167 slidably seals the valve stem against the valve stem guide 161 .
  • an ampule 360 has three spaced apart lugs 382 at its back end.
  • a flare 380 leads into an ampule chamber 384 to guide a contoured end 364 of a plunger 362 to engage the ampule 360 .
  • the plunger shaft 372 has a cruciform cross section to provide a high moment of inertia using minimum material for the disposable plunger and ampule.
  • a collar 374 on the plunger 362 is spaced apart from the tip of the contoured end 364 so that the collar 374 contacts the back surface 388 of the ampule 360 just before the contoured end 364 of the plunger 362 reaches the front end of the ampule 360 . This prevents the contoured end 364 from colliding with the front end of the ampule 360 and overstressing the ampule or buckling the plunger shaft 372 .
  • Webs 376 extending from the plunger shaft 372 support the collar 374 .
  • the back section 390 of the plunger shaft 372 may have teeth or ridges 378 matching the teeth or ridges 240 on the inside surfaces of the clap jaws 236 , a smooth back section 390 is preferred to avoid variations.
  • the cartridge 54 is loaded into the injector 20 by removing or unsnapping the plastic cartridge chamber cover 56 , placing the cartridge 54 into the cartridge chamber 50 , with the neck of the cartridge 54 facing the piercing point 68 , and then replacing the cartridge chamber cover 56 .
  • the cartridge chamber cover 56 snaps into position on the lower housing 44 .
  • a wavy brass liner 32 say be provided in the cartridge chamber 50 to increase thermal conductivity between the cartridge 54 and the injector 20 .
  • the flip handle 80 on the knob 78 is flipped outwardly so that the knob 78 can be more easily tuned.
  • the knob 78 is turned by hand causing the threaded shaft 72 to advance forwardly and drive the piercing body 66 and housing 58 towards the cartridge 54 .
  • the seal 64 engages and seals against a perimeter on the flat end surface of the cartridge 54 .
  • the piercing point 68 engages and pierces the cartridge seal. Compressed gas from the cartridge 54 flows through the bore 70 , into the annulus 62 , through the hole 92 and moves through the bore 96 into the gauge chamber 122 .
  • the seal 64 prevents leakage of compressed gas into the cartridge chamber 50 which remains at ambient pressure.
  • the cartridge seat 52 supports the cartridge 54 longitudinally against the force exerted by the seal 64 and piercing pin 68 .
  • O-rings 60 , 88 and 94 prevent leakage from the passageways from the cartridge 54 to the gauge chamber 122 .
  • the knob 78 moves forward towards the piercing housing nut 76 .
  • the piercing body 66 and housing are in a fully forward position and the back surface of the knob 78 is approximately flush with the back surface of the upper housing 42 .
  • Compressed gas fills the gauge chamber 122 , passes through the filters 130 and 132 , flows through the port 148 (Fig. 3) and into the upper chamber 344 of the initiator valve 144 (Fig. 7).
  • the stem collar spring 346 biases the seat ring 340 on the stem collar 342 against the seat neck 350 , thereby sealing the upper chamber 344 and preventing the compressed gas from moving forward.
  • the cartridge 54 contains a saturated propellant gas, such as CO 2 , in both liquid and gas states, at temperatures near room temperature.
  • a saturated propellant gas such as CO 2
  • the filters 130 and 132 substantially prevent any liquid from the cartridge 54 from passing. This allows the device to be used in any orientation without affecting injection characteristics. Without the filters, liquid CO 2 could pass into the initiator valve 144 and reservoir 168 and flash into gas during actuation of the injector 20 , causing unpredictable injection characteristics.
  • the Bourdon tube 116 which opens into the gauge chamber 122 is also pressurized, The pressure within the Bourdon tube 116 causes it to spiral outwardly resulting in movement of the pointer 102 to indicate the gas pressure on the gauge label 104 (after the gauge body 106 and gauge base 114 have been properly calibrated), The user can then check the available gas pressure within the injector 20 by looking at the pointer 102 through the lens 98 , as shown in Fig. 8.
  • the ampule 360 , plunger 362 and a filling needle may be provided in a sterile package.
  • the filling needle has a fitting to engage the Luer fitting 392 on the ampule.
  • the ampule may be filled in the same way as a conventional needle and syringe, The filling needle is inserted into a vial of injectant and the injectant is drawn up into the ampule by pulling back on the plunger. Dosage is read by the alignment of the red o-ring 366 with volume graduations on the transparent ampule. The filling needle is removed and safely discarded.
  • the ampule is then ready to be placed into the injector, Variable dosage injections are accordingly achieved by loading the ampule in the same manner as for a needle and syringe,
  • the present injector 20 can inject various dosages without adjusting the injector.
  • the ampule 360 may be filled to e.g., 1/3, 1/2, 3/4, etc. of its full volume capacity, Referring to Fig. 10, loading the ampule 360 with differing volumes of injectant will cause the plunger 362 to extend from the ampule 360 by varying amounts.
  • the injector 20 can successfully drive the plunger 362 from any plunger starting position, a single size ampule 360 can be used for various dosage injections. Ampules of varying volumes are not required.
  • the plunger and ampule are installed into the injector 20 .
  • the lugs 382 on the ampule 360 are aligned to pass through the lugs 254 on the front collar 252 .
  • the back end of the plunger 362 is passed Through the front collar 252 , through the return spring 44 and through the clamp piston spring 224 . Since the teeth or ridges 378 on the plunger 362 extend continuously in between the webs 376 and the back end of the plunger, regardless of the dosage carried by the ampule 360 , the teeth 240 of the clamp jaws 236 will over lie the plunger 362 .
  • the back surface 388 of the ampule 360 comes to rest against the pressure plate 248 .
  • the lugs 382 on the ampule 360 fit in between the lugs 258 on the indicator ring 250 .
  • the user then turns the ampule (clockwise as viewed from the front) through an acute angle e.g., approximately 45°, from an ampule loading position to an ampule ready position.
  • the ampule causes the indicator ring 250 to turn with it as the sides of the ampule lugs 382 push against the sides of the indicator ring lugs 258 .
  • a step on each ampule lug prevents the indicator ring and ampule from being turned beyond range.
  • the track on which the detent pin 288 acts is deep enough that the detent cannot be forced out of the track.
  • the two ends of the track act as detent stops.
  • the indicator ring 250 turns and locks into an injection ready position (Fig. 2a)
  • the colored or painted sections on the outside perimeter of the indicator ring 250 moves into view through the view ports 256 . This indicates to the user that the ampule is properly installed in the injector 20 and ready for injection.
  • a cut out 320 in the indicator ring moves into alignment with the hook 264 on the actuator link 262 .
  • the trigger 30 can then be pulled back to actuate the injector 20 to provide an injection to a patient.
  • the actuator link 262 prevents the trigger 30 from moving to actuate the device. Therefore, the injector 20 cannot be actuated unless an ampule is properly installed and aligned in the ready position.
  • the nozzle 386 of the ampule 360 is placed against the patient's skin and the trigger 30 on the actuator slide block 266 is pulled back by the user's index finger.
  • the exhaust valve fork 270 slides the spool valve 286 from an open position (which allows the reservoir 168 to bleed or exhaust through the exhaust bore to ambient) to a closed position wherein the spool valve 286 substantially seals off the reservoir exhaust bore 290 .
  • the reservoir 168 is accordingly sealed off before the slide block end 272 engages the initiator valve cam 274 .
  • the spool valve serves as an exhaust control valve.
  • the slide block end 272 pushes against the initiator valve cam 274 levering the set screw 276 against the initiator valve pin 330 .
  • the sliding movement of the trigger performs three functions: It controls the initiator valve, it controls the spool valve, and it provides an interlock when disabled by the actuator link 262 .
  • the set screw 276 pushes up on the initiator valve pin 330 .
  • the pin socket 332 is driven up against the valve stem 336 causing the stem collar to shift upwardly and separate the seat ring 340 from the seat neck 350 , thereby opening the initiator valve 144 .
  • the valve poppet spring 157 biases the valve poppet 153 toward the valve seat 155 . Gas pressure from the gas inlet 149 drives the poppet 153 into the valve seat 155 creating a gas tight meal.
  • the valve seat 155 is vented on the bottom side 171 to prevent the seat from escaping from the groove 173 .
  • the valve seat retainer 159 retains and vents the valve seal 155 .
  • the valve stem 169 is mechanically isolated from the poppet 153 to assure that the poppet closes without interference from the stem.
  • valve stem 169 slides up and contacts the valve poppet 153 , pushing it away from the valve seat 155 .
  • valve stem spring 165 returns the valve stem to the neutral position and the valve poppet 153 also returns to the closed position.
  • compressed gas flows from the cartridge 54 through the filters and initiator valve 144 , through the reservoir port 154 past the dart 160 and into the reservoir 168 .
  • gas pressure also builds within the poppet chamber 208 , as gas flows from the reservoir 168 through the poppet body supply holes 174 .
  • the clamp piston 210 is driven forward compressing the clamp piston spring 224 and driving the clamp jaws 236 together, through the interaction of the ramp drive 232 on the clamp piston 210 and the clamp piston ramps 234 on the clamp jaws 236 .
  • the teeth 240 on the clamp jaws 236 clamp down and around the plunger 362 .
  • the clamp jaws 236 and their driving mechanism perform two functions: They grab onto the plunger at whatever position the plunger is in, and they transfer driving force from the drive piston to the plunger.
  • the plunger 362 will be fully extended to the rear such that the clamp jaws 236 will engage the plunger 362 close behind the webs 376 .
  • the plunger 362 will extend a shorter distance behind the ampule 360 and the clamp jaws 236 will engage the plunger 362 towards the back end of the plunger.
  • the clamp jaws 236 securely clamp and engage the plunger 362 with the teeth 240 on the clamp jaws 236 locked into the teeth 378 on the plunger 362 .
  • the gas pressure in the clamp piston plenum 216 maintains the engagement of the clamp jaws 236 to the plunger 362 during the injection sequence. As represented in Fig. 12, the clap jaws clap onto the plunger before the poppet valve opens.
  • pressure in the poppet chamber 208 continues to build until it is sufficient to crack the poppet valve 170 open.
  • the poppet spring chamber 226 is sealed from the reservoir 168 and the poppet chamber 208 and is vented to ambient pressure.
  • the rearward acting force resulting from the gas pressure acting on the incline surfaces 152 of the poppet body 172 will exceed the forward acting force of the poppet spring 186 .
  • this "cracking point" is reached, the poppet valve 170 snaps open.
  • the poppet body 172 shifts or slides rearwardly,
  • the sealing edge surface 200 separates from its sealing engagement against the conical poppet seat 188 allowing gas from the reservoir 168 to flow through the poppet chamber 208 to the drive bores 194 .
  • the poppet valve 170 begins to open and the poppet body 172 moves away from the conical poppet seal 188 , the annular front surface 230 of the poppet body 172 is acted on by gas pressure now in the poppet annulus 198 . Since the surface areas acted on by the compressed gas are vastly increased with the addition of the front surface 230 of the poppet body, the force acting on the poppet body 172 rapidly escalates.
  • the poppet valve 170 therefore opens with an "over-center" or hard-over action.
  • the regulation valve 156 closes down via the dart 160 engaging and sealing against the regulation seat 158 .
  • additional gas supply to the reservoir 168 is, at least initially, restricted by the regulation valve 156 , with substantially only the reservoir 168 then acting as a source of compressed gas.
  • pressure regulation of the reservoir is provided through poppet area ratios and spring forces (which may be readily determined for various capacity injectors by those skilled in the art).
  • the reservoir pressure reaches a desired minimum pressure.
  • the drive piston plenum has been supplied by a fixed supply of gas from the reservoir.
  • the spring force acting forwardly on the poppet body, overcomes the net pressure force, acting rearwardly on the poppet body.
  • the poppet body moves forward, lessening the regulation valve restriction to incoming flow.
  • the dart 160 moves with the poppet body away from the seat 158 to allow commencement or increase of gas flow.
  • the opening of the regulator valve consequently increases gas flow into the reservoir and increases the reservoir pressure.
  • the poppet body again moves rearwardly to restrict the incoming flow,
  • the poppet valve and regulator valve act together as a reservoir pressure regulator (and consequently drive piston plenum pressure and ampule pressure).
  • regulation movement when present, occurs generally during the last half of the injection.
  • the CO 2 cartridge is filled with saturated CO 2 .
  • the peak ampule pressure is determined by the poppet valve cracking pressure which is independent of source pressure.
  • the minimum delivery pressure, governed by the pressure regulation is also independent of source pressure. Both of these features are controlled by area ratios and spring rates.
  • the injector is substantially temperature independent.
  • Fig. 12 illustrates the effect of pressure regulation.
  • a smaller dosage of e.g., 1/2 ml or less generally there is no pressure regulation.
  • larger dosages of e.g., over 3/4 ml pressure regulation occurs.
  • intermediate range dosages of e.g., between 1/2 and 3/4 ml some pressure regulation may occur.
  • the rubber or elastomeric face seal 196 adhered to the back of the drive piston 212 assists to rapidly open the poppet valve 170 .
  • the face seal 196 encourages the build up of pressure in the drive bores 194 and poppet annulus 198 before pressurizing the drive plenum 202 . Accordingly, the rapid pressure increase within the drive bores 194 and poppet annulus 198 shorten the time required for opening the poppet valve 170 providing a quick ampule pressure rise time and a more uniform ampule peak pressure.
  • the poppet body supply holes 174 have a large diameter to minimize pressure drop from the reservoir 168 to the poppet chamber 208 .
  • the trigger 30 is held back for longer than necessary for the injection, only a small amount of gas is wasted since all spaces within the injector, except the drive plenum, remain virtually sealed while the trigger is held back.
  • the drive plenum is opened to ambient pressure, but only through orifice 282 which severely restricts flow.
  • the regulation valve 156 restricts flow while the trigger is held back.
  • the trigger is released.
  • the slide block spring 268 assisted by exhaust gas pressure returns the slide block 266 to its forward position.
  • the initiator valve then closes, Then the exhaust valve fork 270 moving with the slide block 266 pulls the spool valve 286 forward reconnecting the spool valve bore 302 and spool plenum 300 to the reservoir exhaust bore 290 .
  • the spool valve and exhaust passage allow the injector to be quickly and quietly reset for another injection, Gas in the reservoir exhausts out through the reservoir exhaust bore 290 and exhaust passage 296 .
  • the exhaust gas pressure in the exhaust passage 296 pushes on the back of the spool valve 286 and helps to return the spool valve and slide block forward to their original ready positions.
  • the slide block spring 268 consequently need only exert a slight force, thereby helping to reduce the finger force necessary to pull the trigger 30 .
  • the drive piston 212 is in the forward position (Fig. 2c), with the plunger shoulder in contact with and exerting a large force on the back end 388 of the ampule 360 .
  • the drive piston return spring 244 , clamp piston spring 224 and jaw springs 238 are compressed.
  • the jaws 236 are engaged with the plunger and the clamp piston 210 is forward. Each part must then return to the ready position.
  • the reservoir 168 Upon release of the trigger 30 , the reservoir 168 is able to rapidly vent to atmosphere.
  • Drive piston plenum gas vents into the reservoir, in part, through the poppet body, until the poppet valve closes, Gas also vents into the reservoir through the cannula 176 , until the holes in the cannula are sealed by the o-ring 190 contained within the poppet seat 188 .
  • This remaining gas which occupies a relatively small volume, and is at a very low pressure, vents through the bleed orifice 282 connecting the drive piston plenum directly to the atmosphere through the drive plenum exhaust bore 284 . Since the orifice 282 is always open, even during the injection, some beneficial drive gas is lost, thus it is a very small, restrictive orifice. Because the orifice 282 is small, if it was the only vent for drive piston plenum gas (i.e., if there were no cannula side holes), venting and reset time would be unacceptably long.
  • the following reset sequence occurs and is controlled by component areas and spring forces, which may be readily determined by those skilled in the art.
  • the clap jaws 236 and clap piston 210 release. This must occur before the drive piston is released so that the plunger is not pulled back.
  • the clamp piston spring force overcomes the opposing pressure force. This release occurs when the drive piston 212 is close to a force equilibrium condition. The pressure force must be close to the opposing spring force. If not, then the drive piston 212 will rapidly return (if the spring force is larger) or plunge forward (if pressure force is larger) causing noise and possible damage to the injector, Thus a force balance is established at the point of plunger release, regardless of the dosage.
  • the drive piston 212 After the plunger release, the drive piston 212 returns as the reservoir bleeds. The drive piston 212 is forced rearward by the drive piston return spring against the opposing pressure force. Gas exhaust and reset occurs quietly and quickly.
  • O-ring 222 serves as a seal and a bumper to quiet the clamp piston return.
  • the plunger 362 is driven forward until the collar 374 contacts the back surface 388 of the ampule 360 . Accordingly, if the trigger 30 is squeezed once and an injection given, released and squeezed again after some delay (i.e., "second fire") without replacing the ampule, the jaws will grab the plunger with the plunger collar in the forward most position, i.e., in contact with the rear ampule face. Thus no forward movement of the drive piston will occur. A second fire does not damage the ampule, plunger or injector.
  • the cannula 176 is attached to and moves with the drive piston 212 .
  • the cannula exhaust hole 190 in the cannula 176 speeds the return stroke of the piston 212 .
  • the poppet valve closes before the drive piston begins its return, Thus a bleed hole in the cannula is required for gas to flow from the drive piston plenum to the reservoir.
  • gas in the drive plenum 202 flows through the cannula exhaust hole 190 through the cannula 176 , back into the reservoir 168 and out through the relatively unobstructed exhaust system of the reservoir exhaust bore 290 and the exhaust passage 296 .
  • the spent ampule and plunger are turned and removed from the injector 20 which is then prepared for the next injection sequence.
  • the ampule and plunger are preferably a single use disposable unit.
  • the plunger may have tapered sections at the front or back which engage a generally complimentary tapered section in the ampule.
  • the injector exerts hundreds of pounds of force on the plunger which drives the tapered section of the plunger of Figs. 10a and 10b into an interference fit with the tapered section of the ampule.
  • the used and non sterile plunger and ampule cannot easily then be re-used.
  • the tapered sections can also act as a plunger stop, in place of the collar on the plunger of Fig. 10, The taper on the plunger and ampule are slightly mismatched and lock together only with high forces (at the end of an injection) and not at low forces (during filling of the ampule).
  • Fig. 10c shows another non-reusable ampule and plunger having a detent. The detent is dimensioned so that only a large force will cause engagement.
  • the injector can be modified to give multiple sequential injections to the same patient.
  • a drive piston stop 394 is added, and acts to stop the drive piston, as the plunger shoulder does in variable delivery.
  • the jaws then disengage and the injector resets.
  • the plunger will automatically be in a "ready” position for the next shot, and the injector may be fired again to deliver the same small dosage.
  • This sequence may be repeated to deliver several small dosage injections until the plunger shoulder contacts the ampule. Dosage may be adjusted by rotating the outer ring 396 to the desired value, indicated by graduations 398 on the injector housing. A longer ampule can be provided to allow for more sequential shots.
  • the present method of needleless injection uses a system of an injector and compatible ampules.
  • the injector is designed to apply a specific force on the plunger of the ampules.
  • the force applied to the plunger by the injector is varied, forming a force - displacement curve.
  • the force applied to the plunger is quite high.
  • the applied force is reduced substantially linearly until the volume injected reaches approximately 0.5 ml, and thereafter the force is held substantially constant.
  • This force displacement curve is independent of the ampule nozzle size.
  • This force - displacement curve translates directly to an ampule pressure - volume injected curve.
  • the injection system employs a singular pressure profile and a family of ampules with various orifice sizes to achieve various depths of penetration.
  • Fig. 17 shows preferred uses of various diameter nozzles with the pressure profile described below.
  • the preferred pressure profile has the following properties: First the pressure rapidly increases from 0 to a value of about 26900-29670 kPa, and preferably about 28290 kPa, (4100 psi) in less than 6 milliseconds (and preferably less than 1 ms). This quick pressure rise avoids "splash-back" and loss of injectant. This pressure range is sufficient to pierce the tissues, but not so high as to cause the excessive pain associated with higher pressures. The pressure is gradually reduced to approximately 8280 - 13800 kPa, and preferably 12420 kPa, (1800 psi) in a generally linear (pressure - volume) fashion corresponding with volume discharged of 0.5 ml.
  • the curve forms an exponential decay.
  • the pressure is held constant until the end of the injection, at which time the pressure abruptly goes to 0 within 5 ms.
  • Final pressures below about 8280 kPa tend to result in "leak-back" of the injectant after the injection,
  • the pressure profile is defined as the pressure immediately proximal to the nozzle.
  • the above- described pressure profile covers an injection larger than approximately 0.5 ml. If the injection is less than this amount, the pressure - profile curve is simply truncated at the end of the delivered volume.
  • Medication viscosity affects penetration of intramuscular injections in a direction contrary to prior art.
  • Experimental data shows that more viscous medications, in the range of from 0.01 to 0.70 poise, have greater fascia penetrating capability, apparently because of reduced turbulence and lower Reynold's number.
  • the present invention also includes the appropriate guidelines for selection of nozzle size with viscous medications.
  • Viscous medications preferably use the same size orifice as for water based medications. Nearly all viscous medications are intramuscular injections, Testing shows that viscous medications have more energy to penetrate the deep fascia than water based medications, but do not go substantially deeper into the muscle. Therefore, the deposition into the muscle is comparable independent of medication viscosity.
  • the present peri-fascial injection is provided by using a nozzle diameter which is smaller than that which would ordinarily be used for an intramuscular injection.
  • the peri-fascial injection is provided by using a SC nozzle (0.10 mm) at an IM injection site preferably with less than 5 mm adipose. This works well because IM sites tend to have very thin layers of adipose tissue.
  • the SC nozzle has sufficient penetrating energy to deposit the medication on the deep fascia when injected into a thin layer of adipose.
  • a peri-fascial injection can also be given at an IM injection site having a 10-15 mm adipose layer using a 0.15 mm diameter nozzle and the above-described pressure profile.
  • the injectant 800 in a peri-fascial injection bores through the skin 802 and adipose 804 , but not the fascia 806 . Rather, the injectant forms a thin layer 808 over the fascia, The thin layer 808 may provide the same pharmacological effect as an IM injection, without penetrating the muscle.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Claims (5)

  1. Verfahren zum Liefern eines Einspritzstrahls durch unter Druck setzen eines fluiden Injektats innerhalb einer Ampulle (360), welches Verfahren die Schritte aufweist:
    einen Tauchkolben (362) mit ausreichender Kraft in eine Ampulle (360) treiben, so daß innerhalb von 6 Millisekunden ein Druck von 26000-30000 kPa erzeugt wird;
    den Druck im allgemeinen linear reduzieren, bis 0,5 ml herausgetrieben werden und der Druck 8000-14000 kPa beträgt;
    den Druck so lange bei 8000-14000 kPa halten, bis ein gewünschtes Volumen an Injektat aus der Ampulle (360) herausgetrieben worden ist; und
    den Druck innerhalb von 5.0 Millisekunden auf ungefähr 0.0 kPa reduzieren.
  2. Verfahren gemäß Anspruch 1, welches weiter den Schritt des Regulierens des Durchmessers der Mündungsöffnung der Ampulle (360) aufweist.
  3. Verfahren gemäß Anspruch 1 oder 2, welches weiter den Schritt des Regulierens der Viskosität des Injektats aufweist.
  4. Verfahren gemäß Anspruch 3, wobei die Viskosität des Injektats im Bereich von 0,01 bis 0,70 Poise liegt.
  5. Verfahren gemäß einem der Ansprüche 1-4, welches weiter den Schritt des Filterns des komprimierten Gases, bevor es in ein Reservoir abgelassen wird, aufweist.
EP93918344A 1992-07-24 1993-07-23 Verfahren für nadellose subkutaninjektionen Expired - Lifetime EP0651663B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/920,106 US5383851A (en) 1992-07-24 1992-07-24 Needleless hypodermic injection device
US920106 1992-07-24
PCT/US1993/006940 WO1994002188A1 (en) 1992-07-24 1993-07-23 Needleless hypodermic injection methods and device

Publications (3)

Publication Number Publication Date
EP0651663A1 EP0651663A1 (de) 1995-05-10
EP0651663A4 EP0651663A4 (de) 1995-08-30
EP0651663B1 true EP0651663B1 (de) 1999-12-01

Family

ID=25443171

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93918344A Expired - Lifetime EP0651663B1 (de) 1992-07-24 1993-07-23 Verfahren für nadellose subkutaninjektionen

Country Status (8)

Country Link
US (3) US5383851A (de)
EP (1) EP0651663B1 (de)
JP (2) JP3633615B2 (de)
AT (1) ATE187083T1 (de)
AU (1) AU676490B2 (de)
CA (1) CA2140772C (de)
DE (1) DE69327165T2 (de)
WO (1) WO1994002188A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43824E1 (en) 2001-01-11 2012-11-20 Powder Pharmaceuticals Inc. Needleless syringe
US8540665B2 (en) 2007-05-04 2013-09-24 Powder Pharmaceuticals Inc. Particle cassettes and processes therefor

Families Citing this family (1096)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2689017B1 (fr) * 1992-03-31 1994-05-27 Mtc Medical Appareil d'injection medicale ou veterinaire.
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5405333A (en) * 1992-12-28 1995-04-11 Richmond; Frank M. Liquid medicament bag with needleless connector fitting using boat assembly
US6206860B1 (en) 1993-07-28 2001-03-27 Frank M. Richmond Spikeless connection and drip chamber with valve
US5540657A (en) * 1994-07-15 1996-07-30 Collagen Corporation Delivery device for injectable materials
DE19519279A1 (de) * 1994-12-07 1996-08-22 Wolfgang Dr Med Wagner Verfahren und Einrichtung zur Saug-Druckinjektion
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
DE29507987U1 (de) * 1995-05-15 1996-09-19 Ferton Holding, Delemont Ejektionsgerät zur Hochdruckejektion einer Flüssigkeit
US5893397A (en) * 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US5865795A (en) 1996-02-29 1999-02-02 Medi-Ject Corporation Safety mechanism for injection devices
US5697917A (en) 1996-02-29 1997-12-16 Medi-Ject Corporation Nozzle assembly with adjustable plunger travel gap
US5921967A (en) 1996-02-29 1999-07-13 Medi-Ject Corporation Plunger for nozzle assembly
US5643211A (en) 1996-02-29 1997-07-01 Medi-Ject Corporation Nozzle assembly having a frangible plunger
US5722953A (en) 1996-02-29 1998-03-03 Medi-Ject Corporation Nozzle assembly for injection device
US5800388A (en) 1996-02-29 1998-09-01 Medi-Ject Corporation Plunger/ram assembly adapted for a fluid injector
US5785688A (en) * 1996-05-07 1998-07-28 Ceramatec, Inc. Fluid delivery apparatus and method
PL186641B1 (pl) * 1996-07-01 2004-02-27 Pharmacia Ab Sposób i urządzenie do dostarczania preparatu
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6106502A (en) * 1996-12-18 2000-08-22 Richmond; Frank M. IV sets with needleless fittings and valves
US5875976A (en) 1996-12-24 1999-03-02 Medi-Ject Corporation Locking mechanism for nozzle assembly
US5993412A (en) * 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US5911703A (en) * 1997-05-22 1999-06-15 Avant Drug Delivery Systems, Inc. Two-stage fluid medicament jet injector
US5947928A (en) * 1997-06-19 1999-09-07 Mile Creek Capital, Llc Drug delivery system
US5964735A (en) * 1997-07-01 1999-10-12 Medisys Technologies, Inc. Fine needle aspiration safety syringe
EP0888790A1 (de) * 1997-07-04 1999-01-07 PowderJect Research Limited Vorrichtung zur Abgabe von Medikamententeilchen
US6569127B1 (en) * 1997-07-18 2003-05-27 Liebel-Flarsheim Company Adapter and syringe for front-loading medical fluid injector
US6171276B1 (en) 1997-08-06 2001-01-09 Pharmacia & Upjohn Ab Automated delivery device and method for its operation
US6071272A (en) * 1997-10-28 2000-06-06 Hoffman; Alan S. Method for treating erectile dysfunctionality
US6610042B2 (en) 1997-12-05 2003-08-26 Felton Medical, Inc. Disposable unit-dose jet-injection syringe for pre-filled and/or transfilled liquid injectable medical drug or vaccine products and method thereof
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US5993418A (en) * 1998-02-24 1999-11-30 Medisys Technologies, Inc. Safety syringe
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
JP2002511396A (ja) 1998-04-14 2002-04-16 メルク エンド カムパニー インコーポレーテッド ポリヌクレオチド製剤の無針投与
KR100622160B1 (ko) 1998-07-27 2006-09-07 안타레스 팔마, 인코퍼레이티드 주사장치.
US6123684A (en) * 1998-07-27 2000-09-26 Medi-Ject Corporation Loading mechanism for medical injector assembly
GB9818110D0 (en) * 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
WO2000012173A1 (en) 1998-08-31 2000-03-09 Johnson & Johnson Consumer Companies, Inc. Electrotransport device comprising blades
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6783509B1 (en) 1998-11-18 2004-08-31 Bioject Inc. Single-use needle-less hypodermic jet injection apparatus and method
US6132395A (en) * 1998-12-08 2000-10-17 Bioject, Inc. Needleless syringe with prefilled cartridge
US6383168B1 (en) * 1998-12-08 2002-05-07 Bioject Medical Technologies Inc. Needleless syringe with prefilled cartridge
US6406455B1 (en) * 1998-12-18 2002-06-18 Biovalve Technologies, Inc. Injection devices
DE19859137C1 (de) * 1998-12-21 2000-05-18 Ferton Holding Sa Ejektionsgerät zur Hochdruckejektion einer Flüssigkeit
US6849060B1 (en) 1999-01-29 2005-02-01 Powderject Research Limited Particle delivery device
US6328714B1 (en) * 1999-01-29 2001-12-11 Powderject Research Limited Particle delivery device
AU4239300A (en) 1999-04-16 2000-11-02 Johnson & Johnson Consumer Companies, Inc. Electrotransport delivery system comprising internal sensors
US7060048B1 (en) * 1999-04-16 2006-06-13 Powerject Research Limited Needleless syringe
AU4656000A (en) * 1999-04-22 2000-11-10 Gilbert Garitano Needleless permanent makeup and tattoo device
US6319230B1 (en) * 1999-05-07 2001-11-20 Scimed Life Systems, Inc. Lateral needle injection apparatus and method
US6689103B1 (en) 1999-05-07 2004-02-10 Scimed Life System, Inc. Injection array apparatus and method
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
EP1187652B1 (de) * 1999-06-02 2006-10-11 Boston Scientific Limited Arzneimittelabgabevorrichtungen
US7147633B2 (en) * 1999-06-02 2006-12-12 Boston Scientific Scimed, Inc. Method and apparatus for treatment of atrial fibrillation
AU6076200A (en) 1999-07-08 2001-01-30 Johnson & Johnson Consumer Companies, Inc. Exothermic bandage
US6890553B1 (en) 1999-07-08 2005-05-10 Johnson & Johnson Consumer Companies, Inc. Exothermic topical delivery device
US6319224B1 (en) * 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US20050027239A1 (en) * 1999-08-20 2005-02-03 Stout Richard R. Intradermal injection system for injecting DNA-based injectables into humans
WO2001013975A2 (en) * 1999-08-20 2001-03-01 Bioject, Inc. Dna-based intramuscular injection system for humans
EP3214175A1 (de) 1999-08-24 2017-09-06 E. R. Squibb & Sons, L.L.C. Humane ctla-4-antikörper und verwendungen davon
US7113821B1 (en) 1999-08-25 2006-09-26 Johnson & Johnson Consumer Companies, Inc. Tissue electroperforation for enhanced drug delivery
US7133717B2 (en) * 1999-08-25 2006-11-07 Johnson & Johnson Consumer Companies, Inc. Tissue electroperforation for enhanced drug delivery and diagnostic sampling
US6626871B1 (en) 1999-10-11 2003-09-30 Felton International, Inc. Method and apparatus for removing cap from medical device
US7074210B2 (en) * 1999-10-11 2006-07-11 Felton International, Inc. Universal protector cap with auto-disable features for needle-free injectors
US20020193740A1 (en) 1999-10-14 2002-12-19 Alchas Paul G. Method of intradermally injecting substances
US6776776B2 (en) * 1999-10-14 2004-08-17 Becton, Dickinson And Company Prefillable intradermal delivery device
US6569143B2 (en) 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US6569123B2 (en) 1999-10-14 2003-05-27 Becton, Dickinson And Company Prefillable intradermal injector
US6843781B2 (en) * 1999-10-14 2005-01-18 Becton, Dickinson And Company Intradermal needle
US6770054B1 (en) 1999-11-23 2004-08-03 Felton International, Inc. Injector assembly with driving means and locking means
DE60029338T2 (de) * 1999-11-23 2007-07-12 Felton International, Inc., Lenexa Injektoranordnung mit antriebs- und verriegelungsmitteln
US7029457B2 (en) * 1999-11-23 2006-04-18 Felton International, Inc. Jet injector with hand piece
US7887506B1 (en) 1999-11-23 2011-02-15 Pulse Needlefree Systems, Inc. Safety mechanism to prevent accidental patient injection and methods of same
US6613026B1 (en) * 1999-12-08 2003-09-02 Scimed Life Systems, Inc. Lateral needle-less injection apparatus and method
US6344027B1 (en) 1999-12-08 2002-02-05 Scimed Life Systems, Inc. Needle-less injection apparatus and method
CA2396569C (en) * 2000-01-07 2010-03-23 Biovalve Technologies, Inc. Injection device
DK1265915T3 (da) 2000-02-23 2011-02-14 Glaxosmithkline Biolog Sa Nye forbindelser
FR2805749B1 (fr) * 2000-03-01 2002-05-17 Poudres & Explosifs Ste Nale Seringue sans aiguille a deux niveaux de vitesse d'injection
US7137968B1 (en) * 2000-03-13 2006-11-21 Nucryst Pharmaceuticals Corp. Transcutaneous medical device dressings and method of use
CN1419458A (zh) * 2000-03-23 2003-05-21 安塔雷斯制药公司 单独使用的一次性喷射式注射器
US6719987B2 (en) 2000-04-17 2004-04-13 Nucryst Pharmaceuticals Corp. Antimicrobial bioabsorbable materials
FR2807946B1 (fr) * 2000-04-19 2002-06-07 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant avec un chargement pyrotechnique bicomposition
US6716190B1 (en) * 2000-04-19 2004-04-06 Scimed Life Systems, Inc. Device and methods for the delivery and injection of therapeutic and diagnostic agents to a target site within a body
US7404815B2 (en) * 2000-05-01 2008-07-29 Lifescan, Inc. Tissue ablation by shear force for sampling biological fluids and delivering active agents
US6689101B2 (en) * 2000-05-22 2004-02-10 Pharmacia Ab Medical arrangement
US6645169B1 (en) * 2000-06-08 2003-11-11 Avant Drug Delivery Systems, Inc. Air-in-tip jet injector
US6406456B1 (en) 2000-06-08 2002-06-18 Avant Drug Delivery Systems, Inc. Jet injector
DE10029325A1 (de) * 2000-06-20 2002-01-03 Peter Lell Nadellose Injektionsvorrichtung mit pyrotechnischem Antrieb
WO2002000174A2 (en) 2000-06-28 2002-01-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7001617B2 (en) 2001-04-23 2006-02-21 Nueryst Pharmaceuticals Corp. Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
US20030206966A1 (en) * 2000-07-27 2003-11-06 Burrell Robert E. Methods of inducing apoptosis and modulating metalloproteinases
US20030180379A1 (en) * 2000-07-27 2003-09-25 Burrell Robert E. Solutions and aerosols of metal-containing compounds
US7008647B2 (en) * 2001-04-23 2006-03-07 Nucryst Pharmaceuticals Corp. Treatment of acne
US7255881B2 (en) * 2000-07-27 2007-08-14 Nucryst Pharmaceuticals Corp. Metal-containing materials
AU7832201A (en) 2000-07-27 2002-02-13 Nucryst Pharm Corp Treatment of hyperproliferative skin disorders and diseases
US20040191329A1 (en) * 2000-07-27 2004-09-30 Burrell Robert E. Compositions and methods of metal-containing materials
US20030185901A1 (en) 2000-07-27 2003-10-02 Burrell Robert E. Methods of treating conditions with a metal-containing material
US7427416B2 (en) * 2000-07-27 2008-09-23 Nucryst Pharmaceuticals Corp. Methods of treating conditions using metal-containing materials
US6989157B2 (en) * 2000-07-27 2006-01-24 Nucryst Pharmaceuticals Corp. Dry powders of metal-containing compounds
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CA2324045A1 (fr) * 2000-10-20 2002-04-20 Universite De Sherbrooke Seringue sans aiguille pour l'injection sous-cutanee de poudres medicamenteuses
FR2815544B1 (fr) 2000-10-23 2003-02-14 Poudres & Explosifs Ste Nale Seringue sans aiguille securisee a architecture compacte
US6652483B2 (en) * 2000-11-07 2003-11-25 Avant Drug Delivery Systems, Inc. Needleless jet injector system with separate drug reservoir
US6626863B1 (en) 2000-11-22 2003-09-30 Nusaf, L.L.C. Safety syringe
WO2002051470A2 (en) * 2000-11-30 2002-07-04 Biovalve Technologies, Inc. Injection systems
DE60212799T2 (de) * 2001-01-18 2006-11-09 Medrad, Inc. Spritzenanschlussflächen und adaptern für verwendung mit medizinische injektoren
US6758837B2 (en) 2001-02-08 2004-07-06 Pharmacia Ab Liquid delivery device and method of use thereof
DE60239594D1 (de) 2001-02-23 2011-05-12 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
US6471669B2 (en) * 2001-03-05 2002-10-29 Bioject Medical Technologies Inc. Disposable needle-free injection apparatus and method
US6645170B2 (en) * 2001-03-05 2003-11-11 Bioject Medical Technologies, Inc. Simplified disposable needle-free injection apparatus and method
US20020139088A1 (en) 2001-03-08 2002-10-03 Archie Woodworth Polymeric syringe body and stopper
US20020172615A1 (en) * 2001-03-08 2002-11-21 Archie Woodworth Apparatus for and method of manufacturing a prefilled sterile container
EP1368104A1 (de) 2001-03-14 2003-12-10 PenJet Corporation Vorrichtung und methode zum entfernen von in lösungen gelöstem gas
ZA200200808B (en) * 2001-03-22 2002-08-12 Roche Diagnostics Gmbh Needleless hypodermic injection system, application device and medication cartridge therefor.
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US7795218B2 (en) 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
US6613010B2 (en) * 2001-04-13 2003-09-02 Penjet Corporation Modular gas-pressured needle-less injector
US20050192530A1 (en) * 2001-04-13 2005-09-01 Penjet Corporation Method and apparatus for needle-less injection with a degassed fluid
ES2261659T3 (es) 2001-04-23 2006-11-16 Nucryst Pharmaceuticals Corp. Un medicamento o una preparacion que contiene un metal tal como plata, oro, platino o paladio como un agente antimicrobiano y su uso para el tratamiento de estados inflamatorios de la piel.
US6755220B2 (en) 2001-04-27 2004-06-29 Penjet Corporation Method and apparatus for filling or refilling a needle-less injector
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US6648850B2 (en) * 2001-06-08 2003-11-18 Bioject, Inc. Durable needle-less jet injector apparatus and method
US20060018877A1 (en) * 2001-06-29 2006-01-26 Mikszta John A Intradermal delivery of vacccines and therapeutic agents
BR0210628A (pt) * 2001-06-29 2004-08-10 Becton Dickinson Co Liberação intradérmica de vacinas e agentes terapêuticos genéticos via microcânula
US7544188B2 (en) * 2001-07-19 2009-06-09 Intelliject, Inc. Medical injector
US7767872B2 (en) * 2001-09-06 2010-08-03 Mpg Biotechnologies, Llc Thimerosal removal device
US8440791B2 (en) * 2001-09-06 2013-05-14 Mgp Biotechnologies, Llc Thimerosal removal device
US6669664B2 (en) 2001-09-07 2003-12-30 Avant Drug Delivery Systems, Inc. Vacuum control cycle for jet injector
EP1427826B1 (de) * 2001-09-20 2011-04-20 Glaxo Group Limited Codon-optimisierte HIV-RT-nef-Gag DNA Impfstoffe
US6824526B2 (en) 2001-10-22 2004-11-30 Penjet Corporation Engine and diffuser for use with a needle-less injector
GB0125506D0 (en) 2001-10-24 2001-12-12 Weston Medical Ltd Needle free injection method and apparatus
ATE350086T1 (de) * 2001-11-09 2007-01-15 Alza Corp Zusammenschiebbarer spritzenbehälter
EP2221076B1 (de) * 2001-11-09 2013-04-10 Alza Corporation Pneumatisch angetriebener Autoinjektor
US6607510B2 (en) 2001-11-09 2003-08-19 Bioject Medical Technologies Inc. Disposable needle-free injection apparatus and method
TWI222370B (en) * 2001-12-14 2004-10-21 Roche Diagnostics Gmbh Needleless hypodermic injection device
CA2476755C (en) 2001-12-17 2014-08-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
AU2003209645A1 (en) * 2002-03-04 2003-09-16 Nano Pass Technologies Ltd. Devices and methods for transporting fluid across a biological barrier
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
JP4594623B2 (ja) 2002-04-12 2010-12-08 シェーリング コーポレイション Ｇタンパク質共役レセプターリガンドおよび方法
AU2003228722B2 (en) 2002-04-25 2009-06-25 Takeda Pharmaceutical Company Limited Treatment of alpha-galactosidase A deficiency
KR101086533B1 (ko) 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
US7238167B2 (en) * 2002-06-04 2007-07-03 Bioject Inc. Needle-free injection system
US6676630B2 (en) 2002-06-04 2004-01-13 Bioject Medical Technologies, Inc. Needle-free injection system
US7156823B2 (en) * 2002-06-04 2007-01-02 Bioject Inc. High workload needle-free injection system
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US6883222B2 (en) * 2002-10-16 2005-04-26 Bioject Inc. Drug cartridge assembly and method of manufacture
MXPA05004022A (es) 2002-10-17 2005-10-05 Genmab As Anticuerpos monoclonales humanos contra cd20.
WO2004037186A2 (en) * 2002-10-22 2004-05-06 Nucryst Pharmaceuticals Corp. Prophylactic treatment methods
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2003275895B2 (en) 2002-11-25 2009-02-05 Tecpharma Licensing Ag Auto-injector comprising a resettable releasing safety device
RU2389732C2 (ru) 2003-01-06 2010-05-20 Корикса Корпорейшн Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
DE602004031589D1 (de) 2003-01-07 2011-04-14 Dyax Corp Kunitz-domäne-bibliothek
CA2814774C (en) 2003-01-31 2016-03-22 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiency disorders
US6935384B2 (en) * 2003-02-19 2005-08-30 Bioject Inc. Needle-free injection system
FR2852517B1 (fr) * 2003-03-21 2005-11-11 Dispositif d'injection sans aiguille a cartouche pyrotechnique et procede d'assemblage d'un tel dispositif
EP1620147A4 (de) * 2003-04-21 2008-06-11 Corium Internat Inc Gerät und verfahren für die repetitive mikrostrahl-arzneimittelabgabe
US20060184101A1 (en) * 2003-04-21 2006-08-17 Ravi Srinivasan Microjet devices and methods for drug delivery
AU2004233346B2 (en) 2003-04-23 2008-03-06 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
CA2525017A1 (en) * 2003-05-09 2004-12-23 Anges Mg, Inc. Needleless syringe having medical agent accommodated therein
EP1664322B1 (de) 2003-05-22 2013-07-10 Fraunhofer USA, Inc. Rekombinantes trägermolekül zur expression, zuführung und reinigung von zielpolypeptiden
WO2005034949A1 (en) * 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
IL157981A (en) 2003-09-17 2014-01-30 Elcam Medical Agricultural Cooperative Ass Ltd Auto injector
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
EA008731B1 (ru) * 2003-11-21 2007-08-31 Чжуншань Ботай Фармасьютик Инструментс Ко., Лтд. Шприц типа предварительного смешивания порошкового лекарства
EP1687026B1 (de) 2003-11-21 2008-05-14 UCB Pharma, S.A. Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität
KR20130133302A (ko) 2003-12-10 2013-12-06 메다렉스, 인코포레이티드 Ｉｐ―１０ 항체 및 그의 용도
PL1711207T3 (pl) 2003-12-10 2013-08-30 Squibb & Sons Llc Przeciwciała przeciwko interferonowi alfa i ich zastosowania
EP1713900A4 (de) * 2004-01-27 2009-06-17 Compugen Ltd Verfahren und systeme zur kommentierung biomolekularer sequenzen
JP5221127B2 (ja) 2004-03-08 2013-06-26 アイコアー メディカル システムズ、インク． 電気を利用した治療剤移送のための改良された装置
IL160891A0 (en) 2004-03-16 2004-08-31 Auto-mix needle
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2566333A1 (en) * 2004-05-19 2005-12-01 Wyeth Modulation of immunoglobulin production and atopic disorders
US7717874B2 (en) * 2004-05-28 2010-05-18 Bioject, Inc. Needle-free injection system
CN102863532A (zh) 2004-06-21 2013-01-09 米德列斯公司 干扰素α受体1抗体及其用途
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
US20060040895A1 (en) * 2004-08-19 2006-02-23 Kipling Thacker Aesthetic use of hyaluronan
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
EP2305294B1 (de) 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Immunogene Zusammensetzung zur Verwendung zur Impfung gegen Staphylokokken
WO2007001448A2 (en) * 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
EP1817590A2 (de) 2004-11-08 2007-08-15 Schering Corporation Tumorassoziation von mdl-1 und entsprechende verfahren
CA2629751A1 (en) 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides
CN103169965A (zh) 2004-11-19 2013-06-26 比奥根艾迪克Ma公司 治疗多发性硬化
US7648482B2 (en) * 2004-11-22 2010-01-19 Intelliject, Inc. Devices, systems, and methods for medicament delivery
US10737028B2 (en) 2004-11-22 2020-08-11 Kaleo, Inc. Devices, systems and methods for medicament delivery
US7648483B2 (en) 2004-11-22 2010-01-19 Intelliject, Inc. Devices, systems and methods for medicament delivery
US11590286B2 (en) 2004-11-22 2023-02-28 Kaleo, Inc. Devices, systems and methods for medicament delivery
US7947017B2 (en) 2004-11-22 2011-05-24 Intelliject, Inc. Devices, systems and methods for medicament delivery
US7749194B2 (en) 2005-02-01 2010-07-06 Intelliject, Inc. Devices, systems, and methods for medicament delivery
CA2791286C (en) 2004-11-22 2015-09-01 Intelliject, Inc. Devices, systems, and methods for medicament delivery
EP2532378B1 (de) * 2004-12-01 2016-04-27 AcuShot, Inc. Nadelloser Injektor
EP1833509A4 (de) * 2004-12-03 2008-12-03 Biogen Idec Inc Verzögerung oder verhinderung des einsetzens von multipler sklerose
PT1828249E (pt) 2004-12-03 2011-02-25 Schering Corp Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r
US7351226B1 (en) * 2004-12-07 2008-04-01 Glenn Herskowitz Medical infusion pump
KR20070095452A (ko) * 2005-01-25 2007-09-28 스카이 제네틱스, 인코포레이티드 암 세포의 세포자멸사를 위한 핵산
US20060183893A1 (en) * 2005-01-25 2006-08-17 North Don A Nucleic acids for apoptosis of cancer cells
US8231573B2 (en) 2005-02-01 2012-07-31 Intelliject, Inc. Medicament delivery device having an electronic circuit system
US8361026B2 (en) 2005-02-01 2013-01-29 Intelliject, Inc. Apparatus and methods for self-administration of vaccines and other medicaments
US9022980B2 (en) * 2005-02-01 2015-05-05 Kaleo, Inc. Medical injector simulation device
US7731686B2 (en) 2005-02-01 2010-06-08 Intelliject, Inc. Devices, systems and methods for medicament delivery
US8206360B2 (en) 2005-02-01 2012-06-26 Intelliject, Inc. Devices, systems and methods for medicament delivery
EP1859277A4 (de) 2005-02-17 2010-03-17 Biogen Idec Inc Behandlung neurologischer störungen
US8207303B2 (en) 2005-02-18 2012-06-26 Medarex, Inc. Monoclonal antibodies against CD30 lacking in fucosyl residues
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
HUE027837T2 (en) 2005-03-23 2016-11-28 Glaxosmithkline Biologicals Sa Adjuvant use of influenza virus and oil-in-water emulsion to induce CD4 T-cell and / or enhanced B-cell cellular response
CN107033243B (zh) 2005-03-23 2020-12-15 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
KR20130114763A (ko) 2005-03-31 2013-10-18 더 제너럴 하스피탈 코포레이션 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정
CA2603385C (en) 2005-04-04 2014-07-15 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues and uses thereof for treating metal overload, oxidative stress, and neoplastic and preneoplastic conditions
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP3782655A1 (de) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. Verfahren zur behandlung der pompe-krankheit unter verwendung von 1-deoxynojirimycin und derivaten
EA018255B1 (ru) 2005-05-27 2013-06-28 Байоджен Айдек Ма Инк. Белки, связывающие tweak, и их применение
US20060271014A1 (en) * 2005-05-31 2006-11-30 Mallinckrodt Inc. Heat retention device for a syringe and methods of use
US20070118093A1 (en) * 2005-06-20 2007-05-24 Von Muhlen Marcio G High-speed jet devices for drug delivery
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
WO2007016643A2 (en) * 2005-08-01 2007-02-08 Mount Sinai School Of Medicine Of New York University A method for extending longevity using npc1l1 antagonists
WO2007117264A2 (en) * 2005-08-03 2007-10-18 Fraunhofer Usa, Inc. Compositions and methods for production of immunoglobulins
US8591457B2 (en) * 2005-08-10 2013-11-26 Alza Corporation Method for making a needle-free jet injection drug delivery device
EP1762575A1 (de) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identifizierung Tumor-assoziierter Antigene für Diagnoseund Therapie
NZ566395A (en) 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
US20070099246A1 (en) * 2005-11-03 2007-05-03 Sandy John D Antibodies, assays and kits to quantitate cartilage destruction
CN103071209A (zh) * 2005-11-17 2013-05-01 周吉尼克斯股份有限公司 用无针注射递送粘稠制剂
EP1790664A1 (de) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
US7695449B2 (en) * 2005-12-05 2010-04-13 Xinming Wang Automatic syringe
ES2390476T3 (es) 2005-12-08 2012-11-13 Medarex, Inc. Anticuerpos monoclonales frente a fucosil-GM1 y procedimientos de uso de anti-fucosil-GM1
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2007070682A2 (en) * 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
LT3017827T (lt) 2005-12-22 2019-01-10 Glaxosmithkline Biologicals S.A. Pneumokokinė polisacharidinė konjuguota vakcina
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
AU2007239095B2 (en) 2006-01-09 2012-05-03 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
US20070166774A1 (en) * 2006-01-17 2007-07-19 Groman Ernest V Functional immunoassay
PT1986612E (pt) 2006-02-07 2012-11-06 Shire Human Genetic Therapies Composição estável de glucocerebrosidase
CA2926975C (en) * 2006-02-09 2019-10-29 Deka Products Limited Partnership Peripheral systems
US8277816B2 (en) * 2006-02-13 2012-10-02 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
US20080279877A1 (en) * 2006-02-13 2008-11-13 Fraunhofer U.S.A. Inc. HPV antigens, vaccine compositions, and related methods
KR20080106433A (ko) * 2006-02-13 2008-12-05 프라운호퍼 유에스에이, 인코포레이티드 인플루엔자 항원, 백신 조성물 및 관련 방법
KR101414762B1 (ko) * 2006-02-17 2014-07-14 알랜 엘 부츠만 카테터 세정 장치
EP1998684A4 (de) * 2006-03-10 2014-09-17 Massachusetts Inst Technology Konjugate und nanosysteme mit ausgelöstem selbstzusammenbau
WO2007111806A2 (en) * 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
US20080045471A1 (en) * 2006-03-27 2008-02-21 North Don A Nucleic Acids For Apoptosis Of Cancer Cells
KR101541383B1 (ko) 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US20090325944A1 (en) * 2006-04-12 2009-12-31 Suzanne Walker Kahne Methods and Compositions for Modulating Glycosylation
US20080003220A1 (en) * 2006-04-21 2008-01-03 Amgen, Inc. Buffering agents for biopharmaceutical formulations
US20070258941A1 (en) * 2006-05-02 2007-11-08 Pfister Brian E Methods and compositions for remediation of disc herniation by modifying structure
CA2652280C (en) 2006-05-15 2014-01-28 Massachusetts Institute Of Technology Polymers for functional particles
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
WO2007140249A1 (en) 2006-05-25 2007-12-06 Biogen Idec Ma Inc. Methods of treating stroke
EP2492684B1 (de) * 2006-06-02 2016-12-28 President and Fellows of Harvard College Neugestaltung von Proteinoberflächen
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
EP2032989B2 (de) 2006-06-30 2015-10-28 Merck Sharp & Dohme Corp. Igfbp2-biomarker
WO2008003319A1 (en) 2006-07-04 2008-01-10 Genmab A/S Cd20 binding molecules for the treatment of copd
SI2422810T1 (sl) 2006-07-17 2015-01-30 Glaxosmithkline Biologicals S.A. Influenčno cepivo
US20080033347A1 (en) * 2006-08-03 2008-02-07 Becton, Dickinson And Company Detachable needle syringe having reduced dead space
US7618396B2 (en) * 2006-08-09 2009-11-17 Avant Medical Corp. Injection system with hidden needles
TW200817437A (en) 2006-08-11 2008-04-16 Medarex Inc Monoclonal antibodies against stromal cell derived factor-1 (SDF-1)
WO2008021367A2 (en) * 2006-08-11 2008-02-21 President And Fellows Of Harvard College Moenomycin biosynthesis-related compositions and methods of use thereof
US20090269342A1 (en) * 2006-08-14 2009-10-29 Massachusetts Institute Of Technology Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto
KR20090050056A (ko) * 2006-08-14 2009-05-19 메사츄세츠 인스티튜트 어브 테크놀로지 헤마글루티닌 폴리펩티드 및 시약 그리고 방법
AU2007292890A1 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
US7942845B2 (en) * 2006-09-19 2011-05-17 Bioject, Inc. Needle-free injector and process for providing serial injections
CA2665239A1 (en) 2006-10-02 2008-05-22 Medarex, Inc. Human antibodies that bind cxcr4 and uses thereof
US7547293B2 (en) 2006-10-06 2009-06-16 Bioject, Inc. Triggering mechanism for needle-free injector
EP2081553B1 (de) * 2006-10-06 2020-08-12 Amgen Inc. Stabile antikörper-formulierungen
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
SI2086582T1 (sl) 2006-10-12 2013-02-28 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega emulzijo olja v vodi kot adjuvans
PT2086582E (pt) 2006-10-12 2013-01-25 Glaxosmithkline Biolog Sa Vacina compreendendo uma emulsão adjuvante óleo em água
PL2068922T3 (pl) 2006-10-19 2012-11-30 Csl Ltd Przeciwciała anty-IL-13R alfa1 i ich zastosowania
EP2094247B1 (de) * 2006-10-20 2022-06-29 Amgen Inc. Stabile polypeptid-formulierungen
KR20090071652A (ko) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
US20090124996A1 (en) * 2006-11-03 2009-05-14 Scott Heneveld Apparatus and methods for injecting high viscosity dermal fillers
NZ577085A (en) 2006-11-15 2012-06-29 Medarex Inc Human monoclonal antibodies to btla and methods of use
WO2008147456A2 (en) * 2006-11-20 2008-12-04 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
JP2010528981A (ja) 2006-12-01 2010-08-26 アンテリオス， インコーポレイテッド 両親媒性実体ナノ粒子
EP2097097B1 (de) 2006-12-01 2018-05-30 E. R. Squibb & Sons, L.L.C. Antikörper, insbesondere menschliche antikörper, die an cd22 binden und deren verwendung
US20090093551A1 (en) * 2006-12-08 2009-04-09 Bhatia Sangeeta N Remotely triggered release from heatable surfaces
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
JP2010513306A (ja) 2006-12-14 2010-04-30 メダレックス インコーポレーティッド Ｃｄ７０に結合するヒト抗体およびその使用
CA2672902C (en) * 2006-12-21 2012-11-27 Amgen Inc. Formulations
EP2474525B1 (de) 2006-12-26 2020-04-15 Lantheus Medical Imaging, Inc. Liganden zur Bildgebung der kardialen Innervation
WO2008083209A2 (en) * 2006-12-29 2008-07-10 Amir Genosar Hypodermic drug delivery reservoir and apparatus
WO2008091838A2 (en) * 2007-01-22 2008-07-31 Intelliject, Inc. Medical injector with compliance tracking and monitoring
EP2118123B1 (de) 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilisierte p53-peptide und deren verwendungen
US9217129B2 (en) * 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
US7744563B2 (en) * 2007-02-23 2010-06-29 Bioject, Inc. Needle-free injection devices and drug delivery systems therefor
EP1970384A1 (de) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
CN104003955A (zh) 2007-03-15 2014-08-27 佛罗里达大学研究基金公司 去铁硫辛聚醚类似物
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2008118970A2 (en) 2007-03-27 2008-10-02 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate light chain sequences
WO2008121767A2 (en) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Stitched polypeptides
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
US20090074828A1 (en) 2007-04-04 2009-03-19 Massachusetts Institute Of Technology Poly(amino acid) targeting moieties
CA2685558A1 (en) * 2007-04-28 2008-11-06 Fraunhofer Usa, Inc. Trypanosoma antigens, vaccine compositions, and related methods
WO2008148057A2 (en) 2007-05-23 2008-12-04 Vical Incorporated Cationic lipids compositions and methods for enhancing immune responses to vaccines
EP1997832A1 (de) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
MX2009013269A (es) 2007-06-05 2010-04-21 Univ Yale Inhibidores de receptor de cinasas de tirosina y metodos de uso de los mismos.
PL2170390T3 (pl) 2007-06-14 2019-05-31 Biogen Ma Inc Preparaty przeciwciała natalizumab
PL2175881T3 (pl) * 2007-06-14 2012-12-31 Crucell Switzerland Ag Śródskórna szczepionka przeciwko grypie
WO2008156676A1 (en) 2007-06-15 2008-12-24 President And Fellows Of Harvard College Methods and compositions for detecting and modulating o-glycosylation
KR20100045445A (ko) 2007-06-26 2010-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
US8404252B2 (en) * 2007-07-11 2013-03-26 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
DE102007034871A1 (de) * 2007-07-24 2009-01-29 Lts Lohmann Therapie-Systeme Ag Einweginjektor mit handbetätigbarem Kolben
EP3255144A1 (de) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering-konstrukt zur herstellung von transgenen mäusen, die menschlische immunoglobulin erzeugen können
US20110059130A1 (en) * 2007-08-20 2011-03-10 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions and methods
EP2190469B1 (de) 2007-09-04 2015-02-25 Compugen Ltd. Polypeptide und polynukleotide und ihre verwendung als zielmolekül zur herstellung von arzneimitteln und biologika
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
EP2205074A4 (de) * 2007-10-04 2013-07-31 Harvard College Moenomycin-analoga, syntheseverfahren und verwendung
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
MX350501B (es) * 2007-10-12 2017-09-07 Massachusetts Inst Technology Nanotecnologia de vacuna.
JP2011500036A (ja) * 2007-10-15 2011-01-06 ザ ユニバーシティー オブ クイーンズランド 構築物系およびその使用
EP2209491B1 (de) 2007-11-02 2015-10-28 Novartis AG Moleküle und verfahren zur modulierung von lrp6 (low-density-lipoprotein receptor-related protein)
ES2445755T3 (es) 2007-11-07 2014-03-05 Celldex Therapeutics, Inc. Anticuerpos que se unen a células dendríticas y epiteliales humanas 205 (DEC-205)
US8617099B2 (en) * 2007-11-26 2013-12-31 Bioject Inc. Injection device plunger auto-disable
US20090137949A1 (en) * 2007-11-26 2009-05-28 Bioject Inc. Needle-free injection device with nozzle auto-disable
JP5737944B2 (ja) 2007-12-17 2015-06-17 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 間質性膀胱炎の治療
EP2231258A1 (de) 2007-12-21 2010-09-29 Aesthetic Sciences Corporation Unabhängige druckinjektionsvorrichtung
EP2240232A4 (de) 2007-12-28 2011-03-16 Aktivpak Inc Spender und therapeutisches paket zur verabreichung einer therapeutischen substanz an eine person
DE102008011873A1 (de) 2007-12-30 2009-07-09 Idelevich, Evgeny Applikationsvorrichtung und -verfahren zur automatisierten Medikamentenabgabe bei arteriellem Hypertonus
AU2009204345A1 (en) * 2008-01-03 2009-07-16 Massachusetts Institute Of Technology Decoy influenza therapies
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CA2712807C (en) 2008-01-22 2019-05-21 Janaina De Souza Ventura Peptides, compositions, and uses thereof
US8039596B2 (en) 2008-02-05 2011-10-18 Bristol-Myers Squibb Company Alpha 5-beta 1 antibodies and their uses
PL2250279T3 (pl) 2008-02-08 2016-11-30 Przeciwciała anty-ifnar1 o zmniejszonym powinowactwie do liganda fc
TW201000107A (en) * 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
JP5749642B2 (ja) 2008-04-16 2015-07-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
EP2273880B1 (de) * 2008-04-28 2014-12-31 Zogenix, Inc. Neuartige formulierungen zur behandlung von migräne
US20110112040A1 (en) * 2008-04-28 2011-05-12 President And Fellows Of Harvard College Supercharged proteins for cell penetration
EP3173424A1 (de) 2008-05-02 2017-05-31 Novartis Ag Verbesserte bindemoleküle auf fibronectin-basis und verwendungen davon
US8021344B2 (en) 2008-07-28 2011-09-20 Intelliject, Inc. Medicament delivery device configured to produce an audible output
USD994111S1 (en) 2008-05-12 2023-08-01 Kaleo, Inc. Medicament delivery device cover
WO2009158145A2 (en) * 2008-05-30 2009-12-30 Allergan, Inc. Injection device for soft-tissue augmentation fillers, bioactive agents and other biocompatible materials in liquid or gel form
AU2009260527A1 (en) 2008-05-30 2009-12-23 Dana-Farber Cancer Institute Inc. Methods of treating a meiotic kinesin-associated disease
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
JP6146949B2 (ja) 2008-06-20 2017-06-21 ノバルティス アーゲー 凝集が低減された免疫グロブリン
BRPI0914630A2 (pt) 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
WO2010009271A2 (en) 2008-07-15 2010-01-21 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
WO2010011313A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligation of stapled polypeptides
KR20110033304A (ko) * 2008-07-23 2011-03-30 메사추세츠 인스티튜트 오브 테크놀로지 Ｄｎａ 손상에 대해 보호하고 신경세포 생존을 증가시키는 히스톤 디아세틸라제 1 (ｈｄａｃ1)의 활성화
CN102177438A (zh) 2008-07-25 2011-09-07 理查德·W·瓦格纳 蛋白筛选方法
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2166021A1 (de) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
ES2824839T3 (es) * 2008-09-18 2021-05-13 Becton Dickinson Co Inyector médico con activación de manguito deslizante
CA2998281C (en) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Human anti-pd-1 antobodies and uses therefor
WO2010037046A1 (en) 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
EP2376089B1 (de) 2008-11-17 2018-03-14 The Regents of the University of Michigan Krebsvakzine-zusammensetzungen und anwendungsverfahren dafür
BRPI0922629A2 (pt) 2008-12-02 2016-01-05 Allergan Inc dispositivo de injeção
US9545483B2 (en) * 2008-12-02 2017-01-17 Sanofi-Aventis Deutschland Gmbh Drive assembly suitable for use in a medication delivery device and medication delivery device
WO2010067345A1 (en) * 2008-12-08 2010-06-17 Perf-Action Technologies Ltd. Erosion prevention for o-rings in a high pressure injection device
US20110311450A1 (en) 2008-12-08 2011-12-22 Zurit Levine Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US9637746B2 (en) 2008-12-15 2017-05-02 Greenlight Biosciences, Inc. Methods for control of flux in metabolic pathways
AU2009328507A1 (en) 2008-12-19 2011-07-14 Medirista Biotechnologies Ab Oxidized cardiolipin as a novel pro-inflammatory factor
KR20110134380A (ko) * 2008-12-22 2011-12-14 그린라이트 바이오사이언시스, 아이엔씨. 화합물의 제조를 위한 조성물 및 방법
ES2639026T3 (es) 2009-03-05 2017-10-25 Oxford Biotherapeutics Ltd. Anticuerpos totalmente humanos específicos para CADM1
GB0904540D0 (en) 2009-03-17 2009-04-29 Biotica Tech Ltd Novel compounds and methods for their production
JP2012523424A (ja) 2009-04-07 2012-10-04 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼの阻害薬
EP2417115A4 (de) 2009-04-07 2012-10-31 Infinity Pharmaceuticals Inc Fettsäureamidhydrolase-hemmer
WO2010118283A1 (en) 2009-04-09 2010-10-14 Amicus Therapeutics, Inc. Methods for preventing and/or treating lysosomal storage disorders
BRPI1011389A2 (pt) * 2009-04-17 2018-07-10 Biogen Idec Inc método para tratar a leucemia mielógena aguda (aml) em um paciente
AP2011005984A0 (en) 2009-04-20 2011-12-31 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17.
US9242040B2 (en) * 2009-04-23 2016-01-26 Bayer Healthcare Llc Syringe assemblies, methods of forming syringe assemblies and adapters for forming syringe assemblies
CA2759942A1 (en) 2009-04-27 2010-10-07 Novartis Ag Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betai subunit
LT2424895T (lt) 2009-04-27 2017-12-27 Novartis Ag Kompozicijos ir būdai, skirti raumenų augimo spartinimui
EP2424877A4 (de) 2009-04-28 2013-01-02 Harvard College Suprageladene proteine zur zellpenetration
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
CN102482345A (zh) 2009-05-13 2012-05-30 航道生物技术有限责任公司 针对流感病毒的中和分子
US9149465B2 (en) * 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en) * 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8927551B2 (en) * 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
WO2010141430A2 (en) 2009-06-01 2010-12-09 Shriners Hospitals For Children A cloned transmembrane receptor for 24-hydroxylated vitamin d compounds and uses thereof
US8974423B2 (en) * 2009-06-01 2015-03-10 Sanofi-Aventis Deutschland Gmbh Resettable drug delivery device
JP2012528858A (ja) 2009-06-01 2012-11-15 プレジデント アンド フェロウズ オブ ハーバード カレッジ Ｏ−ＧｌｃＮＡｃ転移酵素阻害剤およびその使用
PL2896404T3 (pl) 2009-06-04 2017-12-29 Novartis Ag Sposoby identyfikacji miejsc koniugacji IgG
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
US9163330B2 (en) 2009-07-13 2015-10-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
KR20120090037A (ko) 2009-07-31 2012-08-16 메다렉스, 인코포레이티드 Ｂｔｌａ에 대한 완전 인간 항체
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0914589D0 (en) 2009-08-20 2009-09-30 Biotica Tech Ltd Novel compounds and methods for their production
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
EP2480565A4 (de) 2009-09-22 2014-01-01 Aileron Therapeutics Inc Peptidomimetische makrozyklen
GB0916630D0 (en) 2009-09-22 2009-11-04 Secr Defence Antibody
WO2011041391A1 (en) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
WO2011047083A1 (en) 2009-10-13 2011-04-21 Oxford Biotherapeutics Ltd. Antibodies against epha10
JP2013507926A (ja) 2009-10-14 2013-03-07 メリマック ファーマシューティカルズ インコーポレーティッド ＩＧＦ−１Ｒ及びＥｒｂＢ３シグナル伝達を標的とする二重特異的結合剤及びその使用
PT2490533E (pt) 2009-10-19 2016-01-13 Amicus Therapeutics Inc Novas composições para a prevenção e/ou tratamento de distúrbios de depósito lisossómico
EP2490532B1 (de) 2009-10-19 2016-11-23 Amicus Therapeutics, Inc. Neue zusammensetzungen zur prävention und/oder behandlung von degenerativen erkrankungen des zentralnervensystems
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
EP2496944A2 (de) 2009-11-05 2012-09-12 Novartis AG Prädiktive biomarker für die progression von fibrose
EP2507265B1 (de) 2009-12-01 2016-05-11 Compugen Ltd. Heparanase Spice-Variante T5 spezifischer Antikörper und dessen Verwendung.
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US20110137260A1 (en) 2009-12-07 2011-06-09 Allergan, Inc. Slotted syringe
KR101605932B1 (ko) 2009-12-18 2016-03-24 노파르티스 아게 Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물
AU2010334974A1 (en) 2009-12-22 2012-07-12 Novartis Ag Tetravalent CD47-antibody constant region fusion protein for use in therapy
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
AU2011210840B2 (en) 2010-01-27 2014-12-11 Massachusetts Institute Of Technology Engineered polypeptide agents for targeted broad spectrum influenza neutralization
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
CA2788587C (en) 2010-02-03 2020-03-10 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
IN2012DN06588A (de) 2010-02-10 2015-10-23 Novartis Ag
EP2544674B1 (de) 2010-03-08 2017-10-25 Sloan Kettering Institute For Cancer Research Cdc7 kinase hemmer und deren verwendung
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
SG10201504808XA (en) 2010-03-17 2015-07-30 Abbott Res Bv Anti-Nerve Growth Factor (NGF) Antibody Compositions
US9102697B2 (en) 2010-03-22 2015-08-11 President And Fellows Of Harvard College Trioxacarcins and uses thereof
EP2371864A1 (de) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
EP2552947A4 (de) 2010-03-26 2013-11-13 Dartmouth College Vista-regulatorisches t-zellen-mediator-protein, vista-bindende wirkstoffe und verwendung davon
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
WO2011130434A2 (en) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
US20140161794A1 (en) 2010-04-16 2014-06-12 Biogen Idec Ma Inc. Anti-vla-4 antibodies
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
EA034363B1 (ru) 2010-04-23 2020-01-30 Эрроухед Фармасьютикалс, Инк. Фармацевтическая композиция для ингибирования экспрессии гена beta-enac и ее применение
CN103189073B (zh) 2010-05-04 2015-08-12 梅里麦克制药股份有限公司 抗表皮生长因子受体(egfr)的抗体及其用途
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
WO2011140190A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Tetrazolones as inhibitors of fatty acid synthase
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
US8956833B2 (en) 2010-05-07 2015-02-17 Greenlight Biosciences, Inc. Methods for control of flux in metabolic pathways through enzyme relocation
CA2798488C (en) 2010-05-11 2019-06-04 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
EP2756857B1 (de) 2010-05-19 2016-05-18 Allergan, Inc. Modulare Injektionsvorrichtung
JP5857043B2 (ja) 2010-06-18 2016-02-10 大鵬薬品工業株式会社 Ｐｒｐｋ−ｔｐｒｋｂモジュレーター及びその使用
WO2012001647A2 (en) 2010-06-30 2012-01-05 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
WO2016030888A1 (en) 2014-08-26 2016-03-03 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of autoimmune disorders
EP2588122B1 (de) 2010-07-01 2016-03-23 The Texas A&M University System Perlecandomäne v zur rehabilitation nach schlaganfällen und zur wiederherstellung der motorik
EP2593476A2 (de) 2010-07-16 2013-05-22 Ablynx N.V. Modifizierte einzeldomänen-antigen-bindungsmoleküle und ihre verwendung
EP2600901B1 (de) 2010-08-06 2019-03-27 ModernaTX, Inc. Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
WO2012021876A2 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
JP6280367B2 (ja) 2010-08-31 2018-02-14 グリーンライト バイオサイエンシーズ インコーポレーテッドＧｒｅｅｎｌｉｇｈｔ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． プロテアーゼ操作を介した代謝経路におけるフラックスの制御のための方法
CN104958813A (zh) 2010-09-15 2015-10-07 周吉尼克斯股份有限公司 无针注射器和优化注射性能的无针注射器设计参数
WO2012035518A1 (en) 2010-09-17 2012-03-22 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
AU2011305371B2 (en) 2010-09-21 2015-05-21 Massachusetts Institute Of Technology Human-adapted HA polypeptides, vaccines, and influenza treatment
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
US9388230B2 (en) 2010-09-28 2016-07-12 Kahr Medical(2005) Ltd Compositions and methods for treatment of hematological malignancies
WO2012045085A1 (en) 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
ES2587837T3 (es) 2010-10-01 2016-10-27 Biogen Ma Inc. Interferón-beta para su uso como monoterapia o en combinación con otras terapias contra el cáncer
HRP20220796T1 (hr) 2010-10-01 2022-10-14 ModernaTX, Inc. Ribonukleinske kiseline koje sadrže n1-metil-pseudouracil i njihove uporabe
CN103328002B (zh) 2010-10-04 2020-01-14 麻省理工学院 血球凝集素多肽以及与其相关的试剂和方法
CN103154037A (zh) 2010-10-05 2013-06-12 诺瓦提斯公司 抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
EP2635317B1 (de) 2010-11-03 2023-03-08 Construct Medical Pty Ltd Tragbare staubsaugevorrichtung
EP2637669A4 (de) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclische verbindungen und ihre verwendung
JP6017439B2 (ja) 2010-11-24 2016-11-02 ノバルティス・インターナショナル・ファーマシューティカル・リミテッドＮｏｖａｒｔｉｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｌｔｄ． Ｎ−アセチルグルコサミニルトランスフェラーゼ活性を有する融合酵素
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
JP2014501790A (ja) 2011-01-10 2014-01-23 インフィニティー ファーマシューティカルズ， インコーポレイテッド イソキノリノンの調製方法及びイソキノリノンの固体形態
CA2866067C (en) 2011-01-19 2015-04-21 Topokine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
KR20140003573A (ko) 2011-01-24 2014-01-09 안테리오스, 인코퍼레이티드 오일 조성물
KR20140003572A (ko) 2011-01-24 2014-01-09 안테리오스, 인코퍼레이티드 나노입자 조성물
IL293156A (en) 2011-01-24 2022-07-01 Anterios Inc Nanoparticle compounds, their formulations, and their use
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US9173999B2 (en) 2011-01-26 2015-11-03 Kaleo, Inc. Devices and methods for delivering medicaments from a multi-chamber container
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
KR20140010126A (ko) 2011-03-03 2014-01-23 터서스 파마수티칼 엘엘씨 C16:1n7-팔미톨리에이트를 포함하는 조성물들 및 방법들
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
EP2691396B1 (de) 2011-03-30 2016-08-10 Brown University Enopeptine, verwendungen davon und syntheseverfahren dafür
US20130281932A1 (en) * 2011-03-30 2013-10-24 Ziv Harish Palm-based injector actuation and safety surfaces
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
SG194099A1 (en) 2011-04-15 2013-11-29 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
CA2833850A1 (en) * 2011-04-19 2012-10-26 Invisiderm, Llc Method of producing substances with supersaturated gas, transdermal delivery device thereof, and uses thereof
BR112013029514A2 (pt) 2011-05-17 2019-09-24 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, método de tratar ou impedir uma doença
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
JP2014519338A (ja) 2011-06-16 2014-08-14 ノバルティス アーゲー 治療薬として使用される可溶性タンパク質
AU2012273153A1 (en) 2011-06-21 2013-05-02 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
CN103764166B (zh) 2011-06-22 2017-10-24 通用医疗公司 蛋白质病的治疗
PL2726508T3 (pl) 2011-06-28 2017-12-29 Oxford Biotherapeutics Ltd Przeciwciała przeciwko cyklazie ADP-rybozylowej 2
WO2013001517A1 (en) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
HUE040276T2 (hu) 2011-07-01 2019-02-28 Novartis Ag Eljárás metabolikus rendellenességek kezelésére
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
EP2734520B1 (de) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und ihre verwendung
RS58438B1 (sr) 2011-07-22 2019-04-30 Massachusetts Inst Technology Aktivatori klase i histonskih deacetilaza (hdacs) i njihova primena
CA2842860A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Sur-binding proteins
RU2014111823A (ru) 2011-08-29 2015-10-10 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
EP3521432A1 (de) 2011-09-02 2019-08-07 Arrowhead Pharmaceuticals, Inc. Organische zusammensetzungen zur behandlung von hsf1-bedingten erkrankungen
CN104159890B (zh) 2011-09-09 2018-04-10 蓝瑟斯医学影像公司 用于合成和使用显像剂的组合物、方法和系统
CN104093848A (zh) 2011-09-09 2014-10-08 绿光生物科学公司 碳青霉烯(carbapenem)的无细胞制备
WO2013039861A2 (en) 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
BR112014006822B1 (pt) 2011-09-22 2021-05-18 Amgen Inc. Proteína de ligação ao antígeno cd27l, composição compreendendo uma proteína de ligação ao antígeno cd27l, ácido nucleico isolado, vetor de expressão, célula hospedeira recombinante procariótica, método de preparação de um conjugado de droga e anticorpo cd27l e uso de uma proteína de ligação ao antígeno cd27l
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
EP3492109B1 (de) 2011-10-03 2020-03-04 ModernaTX, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
RU2474437C1 (ru) * 2011-10-13 2013-02-10 Борис Владимирович Смоляров Способ осуществления безыгольной инъекции
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
AU2012326026B2 (en) 2011-10-18 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
CA2855155A1 (en) 2011-11-09 2013-05-16 Bristol-Myers Squibb Company Treatment of hematologic malignancies with an anti-cxcr4 antibody
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
US8603028B2 (en) 2011-11-18 2013-12-10 Allergan, Inc. Injection device having an angled tip portion
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
CN104114170B (zh) 2011-12-16 2021-07-06 佛罗里达大学研究基金会 4′-去铁硫素类似物的用途
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
EP2793940B1 (de) 2011-12-22 2018-11-14 i2 Pharmaceuticals, Inc. Surrogatbindungsproteine
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
US9567596B2 (en) 2012-01-05 2017-02-14 Glykos Finland Oy Protease deficient filamentous fungal cells and methods of use thereof
CA2860676A1 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
US10130800B2 (en) 2012-01-27 2018-11-20 Invisiderm, Llc Method of producing substances with supersaturated gas, transdermal delivery device thereof, and uses thereof
SG2014008304A (en) 2012-02-01 2014-06-27 Compugen Ltd C10rf32 antibodies, and uses thereof for treatment of cancer
JP6113194B2 (ja) 2012-02-13 2017-04-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ エンジイン化合物、その抱合体、ならびにその使用および方法
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
WO2013142796A2 (en) 2012-03-23 2013-09-26 Bristol-Myers Squibb Company Methods of treatments using ctla4 antibodies
WO2013148103A1 (en) 2012-03-27 2013-10-03 Amicus Therapeutics, Inc. Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system
CN104203280A (zh) 2012-03-27 2014-12-10 诺华股份有限公司 纤维化的治疗
WO2013152279A1 (en) 2012-04-06 2013-10-10 President And Fellows Of Harvard College Chemoenzymatic methods for synthesizing moenomycin analogs
US9273084B2 (en) 2012-04-06 2016-03-01 President And Fellows Of Harvard College Moenomycin analogs, methods of synthesis, and uses thereof
EP2850091A1 (de) 2012-04-06 2015-03-25 President and Fellows of Harvard College Verfahren und verbindungen zur identifizierung von glycosyltransferaseinhibitoren
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
US20130304017A1 (en) * 2012-05-09 2013-11-14 Bioject, Inc. Peformance of needle-free injection according to known relationships
EP3492101A3 (de) 2012-05-10 2019-10-23 Massachusetts Institute Of Technology Mittel zur influenzaneutralisierung
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US9399672B2 (en) 2012-05-17 2016-07-26 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Hepatitis C virus neutralizing antibody
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
US9522235B2 (en) 2012-05-22 2016-12-20 Kaleo, Inc. Devices and methods for delivering medicaments from a multi-chamber container
DK2852610T3 (en) 2012-05-23 2018-09-03 Glykos Finland Oy PRODUCTION OF FUCOSYLED GLYCOPROTEIN
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
KR20150021088A (ko) 2012-06-05 2015-02-27 디 오스트레일리언 내셔널 유니버시티 인터루킨-4 길항제를 이용한 백신접종
GB201210082D0 (en) * 2012-06-07 2012-07-25 Consort Medical Plc Improved syringe
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
US10309430B2 (en) * 2012-08-10 2019-06-04 Confluent Surgical, Inc. Pneumatic actuation assembly
WO2014028463A1 (en) 2012-08-14 2014-02-20 Allergan, Inc. Syringe for mixing and dispensing adipose tissue
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
PT2920197T (pt) 2012-09-26 2021-06-11 Harvard College Péptidos agrafados com bloqueio de prolina e suas utilizações
WO2014055564A1 (en) 2012-10-01 2014-04-10 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
LT2909204T (lt) 2012-10-12 2019-05-10 The Broad Institute, Inc. Gsk3 inhibitoriai ir jų panaudojimo būdai
EP2909194A1 (de) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Hemmer der cyclinabhängigen kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US9675754B2 (en) 2012-10-24 2017-06-13 Nuance Designs, LLC Autoinjector
WO2014065822A1 (en) 2012-10-26 2014-05-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hepatitis c virus neutralizing epitopes, antibodies, and methods
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
DK2914296T4 (da) 2012-11-01 2022-01-03 Infinity Pharmaceuticals Inc Behandling af cancere under anvendelse af PI3-kinase-isoform-modulatorer
EP2917203B1 (de) 2012-11-02 2019-04-03 Dana-Farber Cancer Institute, Inc. Verfahren zur identifizierung von myc inhibitoren
AU2013344815B2 (en) * 2012-11-13 2018-07-26 Construct Medical Pty Ltd A portable suction device
CA2869676C (en) 2012-11-21 2015-06-23 Topokine Therapeutics, Inc. Uses and compositions comprising a thiazolidinedione and oleic acid for locally increasing subcutaneous fat
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US9775915B2 (en) 2012-11-26 2017-10-03 President And Fellows Of Harvard College Trioxacarcins, trioxacarcin-antibody conjugates, and uses thereof
MX363407B (es) 2012-12-10 2019-03-22 Biogen Ma Inc Anticuerpos del antigeno 2 de celulas dendriticas anti-sangre y usos de los mismos.
ES2756330T3 (es) 2012-12-18 2020-04-27 Novartis Ag Polipéptidos de factor de crecimiento insulínico estabilizados
CA2894126A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
WO2014100716A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
GB2523512A (en) 2012-12-27 2015-08-26 Kaleo Inc Devices, systems and methods for locating and interacting with medicament delivery systems
EP3434774A1 (de) 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor-polynukleotide zur veränderung zellulärer phänotypen
WO2014114801A1 (en) 2013-01-25 2014-07-31 Amgen Inc. Antibodies targeting cdh19 for melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
CN105263954B (zh) 2013-02-07 2019-12-03 麻省理工学院 H5流感的人类适应
EP4272750A3 (de) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Proteinantigene zum schutz gegen pneumokokkenkolonisation und/oder -befall
CU24300B1 (es) 2013-02-08 2017-12-08 Novartis Ag Anticuerpos anti-il-17a útiles en el tratamiento de trastornos autoinmunes e inflamatorios
EA030830B1 (ru) 2013-02-14 2018-10-31 Бристол-Майерс Сквибб Компани Соединения тубулизина, способы их получения и применение
EP2962100B1 (de) 2013-02-28 2021-07-28 Caprion Proteomics Inc. Tuberkulose biomarker und deren verwendung
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
SG10201913593WA (en) 2013-03-13 2020-02-27 Harvard College Stapled and stitched polypeptides and uses thereof
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
CA2899449A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing the same using displacement chromatography
CA2926301A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
LT2970449T (lt) 2013-03-15 2019-11-25 Amgen Res Munich Gmbh Viengrandės surišančios molekulės, apimančios n galo abp
WO2014140368A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Antibody constructs for influenza m2 and cd3
MX2015011670A (es) 2013-03-15 2016-03-31 Biogen Ma Inc Tratamiento y prevencion de lesion renal aguda usando anticuerpos anti-alfa v beta 5.
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
EP3760223A1 (de) 2013-04-03 2021-01-06 N-Fold Llc Neuartige nanopartikelzusammensetzungen
US9982005B2 (en) 2013-04-04 2018-05-29 President And Fellows Of Harvard College Macrolides and methods of their preparation and use
EP2983659B1 (de) 2013-04-09 2019-11-20 Massachusetts Institute of Technology Wirkstofffreisetzendes polymer und verwendungen davon
US10301359B2 (en) 2013-04-30 2019-05-28 Massachusetts Institute Of Technology Human adaptation of H3 influenza
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
NO2753788T3 (de) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US20140350518A1 (en) 2013-05-23 2014-11-27 Allergan, Inc. Syringe extrusion accessory
US20140350516A1 (en) 2013-05-23 2014-11-27 Allergan, Inc. Mechanical syringe accessory
EP3004167B1 (de) 2013-05-30 2018-07-25 Kiniksa Pharmaceuticals, Ltd. Oncostatin-m-rezeptor-antigenbindende proteine
AU2014273946B2 (en) 2013-05-30 2020-03-12 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
WO2014197723A2 (en) 2013-06-05 2014-12-11 Massachusetts Institute Of Technology Human adaptation of h7 ha
WO2014201127A2 (en) 2013-06-11 2014-12-18 Kala Pharmaceuticals, Inc. Urea derivatives and uses thereof
CA2915354A1 (en) 2013-06-14 2014-12-18 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
WO2014207067A1 (en) 2013-06-26 2014-12-31 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) The (s)-enantiomer of mepazine
EP3013365B1 (de) 2013-06-26 2019-06-05 Academia Sinica Rm2-antigene und verwendung davon
EP3013347B1 (de) 2013-06-27 2019-12-11 Academia Sinica Glykankonjugate und verwendung davon
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
CN105658807A (zh) 2013-08-05 2016-06-08 绿光生物科技股份有限公司 具有蛋白酶切割位点的工程化蛋白
KR20160040290A (ko) 2013-08-05 2016-04-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 조합 면역원성 조성물
TWI532511B (zh) * 2013-08-16 2016-05-11 京華堂實業股份有限公司 無針型注射系統及其注射方法
CN105682666B (zh) 2013-09-06 2021-06-01 中央研究院 使用醣脂激活人类iNKT细胞
TWI688401B (zh) 2013-09-13 2020-03-21 美商安進公司 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
EP3052123A1 (de) 2013-10-02 2016-08-10 Novartis Ag Insulinähnliche wachstumsfaktor-mimetika zur verwendung in einer therapie
EP3052128A2 (de) 2013-10-04 2016-08-10 Biogen MA Inc. Tweak-antagonisten zur behandlung von lupus nephritis und muskelatrophie
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PL3052485T3 (pl) 2013-10-04 2022-02-28 Infinity Pharmaceuticals, Inc. Związki heterocykliczne i ich zastosowania
PT3055331T (pt) 2013-10-11 2021-04-05 Oxford Bio Therapeutics Ltd Anticorpos conjugados contra ly75 para o tratamento de cancro
WO2015057894A1 (en) 2013-10-15 2015-04-23 Massachusetts Institute Of Technology Methods for treating polycystic kidney disease and polycystic liver disease
WO2015057958A2 (en) 2013-10-16 2015-04-23 Massachusetts Institute Of Technology Enterobactin conjugates and uses thereof
EP3057955B1 (de) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Zur behandlung von proliferativen erkrankungen geeignete heteroaromatische verbindungen
WO2015057939A1 (en) 2013-10-18 2015-04-23 Biogen Idec Ma Inc. Anti-s1p4 antibodies and uses thereof
WO2015058140A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX355330B (es) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapeuticos y sus usos.
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
US10023636B2 (en) 2013-12-20 2018-07-17 Intervet Inc. Caninized murine antibodies to human PD-1
TWI670283B (zh) 2013-12-23 2019-09-01 美商建南德克公司 抗體及使用方法
CN106661107B (zh) 2013-12-24 2021-12-24 杨森制药公司 抗vista抗体及片段
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
CA2934819A1 (en) 2013-12-24 2015-07-02 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2015109180A2 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
EA201691603A1 (ru) 2014-02-12 2016-11-30 Амикус Терапьютикс, Инк. Производные сахаров, содержащие серосодержащие фрагменты, способы их получения и способы их применения для лечения mps iiic
AU2015226911B2 (en) 2014-03-07 2018-03-01 The Arizona Board Of Regents On Behalf Of The University Of Arizona Non-narcotic CRMP2 peptides targeting sodium channels for chronic pain
SG11201607705XA (en) 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
TWI797430B (zh) 2014-03-27 2023-04-01 中央研究院 反應性標記化合物及其用途
EP3122375B1 (de) 2014-03-28 2021-03-03 University of Washington through its Center for Commercialization Impfungen gegen brust- und eierstockkrebs
US9675627B2 (en) 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
US10039816B2 (en) 2014-04-30 2018-08-07 Massachusetts Institute Of Technology Siderophore-based immunization against gram-negative bacteria
US10029048B2 (en) 2014-05-13 2018-07-24 Allergan, Inc. High force injection devices
WO2015179635A2 (en) 2014-05-21 2015-11-26 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
JP7062361B2 (ja) 2014-05-27 2022-05-06 アカデミア シニカ 抗ｈｅｒ２糖操作抗体群およびその使用
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR102576850B1 (ko) 2014-05-27 2023-09-11 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
KR102494193B1 (ko) 2014-05-28 2023-01-31 아카데미아 시니카 항-ｔｎｆ-알파 글리코항체 및 이의 용도
JP6612017B2 (ja) * 2014-06-03 2019-11-27 株式会社ダイセル 無針注射器による注射システム
EA037006B1 (ru) 2014-06-06 2021-01-26 Бристол-Майерс Сквибб Компани Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
WO2015191881A2 (en) 2014-06-11 2015-12-17 Green Kathy A Use of vista agonists and antagonists to suppress or enhance humoral immunity
US11571472B2 (en) 2014-06-13 2023-02-07 Glaxosmithkline Biologicals Sa Immunogenic combinations
MA40240B1 (fr) 2014-06-19 2019-03-29 Ariad Pharma Inc Composés hétéroaryle d'inhibition de la kinase
EP2959931A1 (de) 2014-06-24 2015-12-30 LTS LOHMANN Therapie-Systeme AG Nadellose Injektionsvorrichtung
EP3161001A2 (de) 2014-06-25 2017-05-03 Novartis AG Il17-a spezifische antikörper die mit hyaluronan bindenden peptid-marker fusioniert sind
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
WO2016004197A1 (en) 2014-07-03 2016-01-07 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
US20160185848A1 (en) 2014-07-09 2016-06-30 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using sugars
EP3169699A4 (de) 2014-07-18 2018-06-20 The University of Washington Krebsimpfstoffzusammensetzungen und verfahren zur verwendung davon
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
US20170275373A1 (en) 2014-07-31 2017-09-28 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
AU2015294834B2 (en) 2014-07-31 2021-04-29 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
EP2979714A1 (de) 2014-08-02 2016-02-03 LTS LOHMANN Therapie-Systeme AG Nadellose Injektionsvorrichtung aufweisend eine Membran
CA2958018A1 (en) 2014-08-11 2016-02-18 University Of Massachusetts Anti-ospa antibodies and methods of use
US10736966B2 (en) 2014-08-12 2020-08-11 Massachusetts Institute Of Technology Brush-poly (glycoamidoamine)-lipids and uses thereof
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CN113583131B (zh) 2014-08-19 2024-09-03 默沙东有限责任公司 抗tigit抗体
EP2993174A1 (de) 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridinderivate und deren Verwendung in der Therapie
JP6899321B2 (ja) 2014-09-08 2021-07-07 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 糖脂質を使用するヒトｉＮＫＴ細胞活性化
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
US10226585B2 (en) 2014-10-01 2019-03-12 Allergan, Inc. Devices for injection and dosing
SG11201702606TA (en) 2014-10-03 2017-04-27 Massachusetts Inst Technology Antibodies that bind ebola glycoprotein and uses thereof
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
KR102331856B1 (ko) 2014-10-21 2021-11-29 다케다 야쿠힌 고교 가부시키가이샤 결정 형태의 5-클로로-n4-[2-(디메틸포스포릴)페닐]-n2-｛2-메톡시-4-[4-(4-메틸피페라진-1-일)피페리딘-1-일]피리미딘-2,4-디아민
EP3011988A1 (de) 2014-10-22 2016-04-27 LTS LOHMANN Therapie-Systeme AG Nadellose Injektionsvorrichtung aufweisend ein Gel und eine Membran
EP3212222A2 (de) 2014-10-28 2017-09-06 INSERM - Institut National de la Santé et de la Recherche Médicale Zusammensetzungen und verfahren für antigenspezifische toleranz
WO2016075137A1 (en) 2014-11-10 2016-05-19 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death
WO2016077125A1 (en) 2014-11-10 2016-05-19 Moderna Therapeutics, Inc. Alternative nucleic acid molecules containing reduced uracil content and uses thereof
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
ME03806B (de) 2014-11-21 2021-04-20 Bristol Myers Squibb Co Antikörper gegen cd73 und verwendungen davon
CN107250157B (zh) 2014-11-21 2021-06-29 百时美施贵宝公司 包含修饰的重链恒定区的抗体
WO2016086026A1 (en) 2014-11-26 2016-06-02 Kala Pharmaceuticals, Inc. Crystalline forms of a therapeutic compound and uses thereof
US20170269092A1 (en) 2014-12-02 2017-09-21 Cemm - Forschungszentrum Fuer Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
CN107405398A (zh) 2014-12-05 2017-11-28 伊穆奈克斯特股份有限公司 鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
CA2969467A1 (en) 2014-12-10 2016-06-16 Kala Pharmaceuticals, Inc. 1-amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
CA2971542A1 (en) 2014-12-19 2016-06-23 Regenesance B.V. Antibodies that bind human c6 and uses thereof
SG11201705063VA (en) 2014-12-23 2017-07-28 Bristol Myers Squibb Co Antibodies to tigit
JP7358029B2 (ja) 2014-12-23 2023-10-10 スローン － ケタリング・インスティテュート・フォー・キャンサー・リサーチ グラナチシンｂの多形体
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10538596B2 (en) 2015-01-09 2020-01-21 Adalta Limited CXCR4 binding molecules and methods of use thereof
CN107231804B (zh) 2015-01-14 2019-11-26 百时美施贵宝公司 亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI736523B (zh) 2015-01-24 2021-08-21 中央研究院 新穎聚醣結合物及其使用方法
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US10983128B2 (en) 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
WO2016144773A1 (en) 2015-03-06 2016-09-15 Abbvie Inc. Arabinosylated glycoproteins
EP3268037B1 (de) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
CA2976544A1 (en) 2015-03-10 2016-09-15 Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company Multiple needle injector
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
JP2018511655A (ja) 2015-03-20 2018-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2016235054B2 (en) 2015-03-24 2020-07-16 Kaleo, Inc. Devices and methods for delivering a lyophilized medicament
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
SG11201707370WA (en) 2015-03-30 2017-10-30 Greenlight Biosciences Inc Cell-free production of ribonucleic acid
DK3277722T3 (da) 2015-04-02 2021-10-11 Intervet Int Bv Antistoffer mod canin interleukin-4 receptor alpha
WO2016164937A2 (en) 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
RU2017130313A (ru) 2015-04-10 2019-05-13 Гельмгольц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) Производные пирона для применения в терапии
BR112017021696A2 (pt) 2015-04-10 2018-07-10 Amgen Inc muteínas de interleucina-2 para a expansão de células t regulatórias
JP6907124B2 (ja) 2015-04-17 2021-07-21 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ Ｃｄｈ３及びｃｄ３に対する二重特異性抗体構築物
WO2016176343A1 (en) 2015-04-27 2016-11-03 University Of Florida Research Foundation, Incorporated Metabolically programmed metal chelators and uses thereof
MX2017013807A (es) 2015-04-30 2018-03-15 Harvard College Anticuerpos anti-proteina de union al lipido de adipocito humana (ap2) y agente de union al antigeno para tratar trastornos metabolicos.
WO2016178591A2 (en) 2015-05-05 2016-11-10 Gene Predit, Sa Genetic markers and treatment of male obesity
CN107849142B (zh) 2015-05-15 2022-04-26 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
US10568852B2 (en) 2015-05-22 2020-02-25 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Combination compositions and their use in methods for treating obesity and obesity-related disorders
WO2016189045A1 (en) 2015-05-27 2016-12-01 Ucb Biopharma Sprl Method for the treatment of neurological disease
WO2016196895A1 (en) * 2015-06-05 2016-12-08 Joslin Diabetes Center, Inc. Methods amd compositions for promoting thermogenic potential
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
AU2016280702A1 (en) * 2015-06-15 2018-02-01 Nuance Designs Of Ct, Llc Gas-propelled autoinjector with gas flow regulator
JP2017000667A (ja) 2015-06-16 2017-01-05 国立大学法人三重大学 無針注射器及びそれを用いた注射対象領域へのｄｎａ導入方法
LT3310764T (lt) 2015-06-19 2023-06-12 Massachusetts Institute Of Technology Alkenilu pakeisti 2,5-piperazindionai ir jų panaudojimas kompozicijose, skirtose agento pristatymui į subjektą ar ląstelę
DK3313882T3 (da) 2015-06-24 2020-05-11 Janssen Pharmaceutica Nv Anti-VISTA antistoffer og fragmenter
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
WO2017004016A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
AU2016287571C1 (en) 2015-06-30 2021-12-23 Kaleo, Inc. Auto-injectors for administration of a medicament within a prefilled syringe
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3322733B1 (de) 2015-07-13 2021-09-15 Compugen Ltd. Hide1-zusammensetzungen und verfahren
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
US10179128B2 (en) 2015-08-31 2019-01-15 Amicus Therapeutics, Inc. Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
RS63030B1 (sr) 2015-09-17 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
AU2016324463B2 (en) 2015-09-17 2022-10-27 Modernatx, Inc. Polynucleotides containing a stabilizing tail region
RU2638457C2 (ru) 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
EP3355914B1 (de) 2015-09-29 2024-03-06 The General Hospital Corporation Eine bcg-haltige zusammensetzung zur cholesterolsenkung.
AU2016330773A1 (en) 2015-09-30 2018-04-19 Charité-Universitätsmedizin Berlin Method of treating melanocortin-4 receptor pathway-associated disorders
WO2017059389A1 (en) 2015-10-01 2017-04-06 Kythera Biopharmaceuticals, Inc. Compositions comprising a statin for use in methods of adipolysis
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
WO2017079768A1 (en) 2015-11-08 2017-05-11 Genentech, Inc. Methods of screening for multispecific antibodies
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
ES2926969T3 (es) 2015-11-19 2022-10-31 Bristol Myers Squibb Co Anticuerpos contra el receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos
UY36990A (es) 2015-11-21 2017-11-30 Fundació Privada Inst De Recerca De La Sida-Caixa (Irsicaixa) Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria
PT3383920T (pt) 2015-11-30 2024-04-15 Univ California Entrega de carga útil específica para tumores e ativação imune utilizando um anticorpo humano que tem como alvo um antigénio altamente específico da superfície das células tumorais
CN108602885B (zh) 2015-11-30 2022-05-24 百时美施贵宝公司 抗人ip-10抗体及其用途
CN108601951B (zh) 2015-12-09 2022-11-22 金港医疗(澳大利亚)私人有限公司 用于治疗的免疫调节组合物
LT3394030T (lt) 2015-12-22 2022-04-11 Modernatx, Inc. Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
WO2017127468A1 (en) 2016-01-22 2017-07-27 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
TWI797073B (zh) 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
HUE057220T2 (hu) 2016-02-03 2022-04-28 Amgen Res Munich Gmbh BCMA és CD3 bispecifikus, T-sejtet kötõ antitest-konstrukciók
SG11201806150RA (en) 2016-02-03 2018-08-30 Amgen Res Munich Gmbh Psma and cd3 bispecific t cell engaging antibody constructs
CA3014013A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
RU2018131123A (ru) 2016-02-17 2020-03-17 Новартис Аг Антитела к tgf-бета2
CN109195629A (zh) 2016-02-24 2019-01-11 威特拉公司 流行性感冒抗体分子制剂
IL295230A (en) 2016-03-04 2022-10-01 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
WO2017151176A1 (en) 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
JP2019515876A (ja) 2016-03-08 2019-06-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｎ−グリカンおよびそのアレイのモジュール合成のための方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
BR112018069659A2 (pt) 2016-03-28 2019-02-12 Ichor Medical Systems, Inc. método e aparelho para aplicação de agentes terapêuticos
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
KR102536687B1 (ko) 2016-04-06 2023-05-25 그린라이트 바이오사이언시스, 아이엔씨. 리보핵산의 무세포 생산
KR102232054B1 (ko) 2016-04-08 2021-03-26 알레간 인코포레이티드 흡인 및 주입 디바이스
CR20180537A (es) 2016-04-15 2019-03-04 Immunext Inc Anticuerpos vista antihumanos y su uso
US20190255143A1 (en) 2016-04-18 2019-08-22 The Trustees Of Columbia University In The City Of New York Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash)
EP3445783A2 (de) 2016-04-18 2019-02-27 Celldex Therapeutics, Inc. Agonistische antikörper zur bindung von humanem cd40 und verwendungen davon
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
CA3019588A1 (en) 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
PL3445850T3 (pl) 2016-04-22 2022-01-17 BioNTech SE Sposoby otrzymywania jednoniciowego rna
EP3448465B1 (de) * 2016-04-29 2021-06-02 Altaviz LLC Selbständig energieversorgte spritze
AU2017264578A1 (en) 2016-05-09 2019-01-03 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
KR20230061583A (ko) 2016-06-03 2023-05-08 사노피 파스퇴르 인코포레이티드 조작된 인플루엔자 헤마글루티닌 폴리펩티드의 변형
US10105449B2 (en) 2016-06-07 2018-10-23 Massachusetts Institute Of Technology Drug delivery polymers and uses thereof
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2019525901A (ja) 2016-06-14 2019-09-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 脂質ナノ粒子の安定化製剤
CA3025869A1 (en) 2016-06-14 2017-12-21 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
US20180002417A1 (en) 2016-06-15 2018-01-04 Celimmune Llc Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US10328205B2 (en) * 2016-07-07 2019-06-25 Shl Medical Ag Drug delivery device with pneumatic power pack
UY37325A (es) 2016-07-14 2018-01-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Anticuerpos monoclonales que se enlazan a tim3 para estimular respuestas inmunitarias y composiciones que los contienen
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
US20180028755A1 (en) 2016-07-28 2018-02-01 Portal Instruments, Inc. Connected health platform including needle-free injector system
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2018027042A1 (en) 2016-08-03 2018-02-08 Bio-Techne Corporation Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
SG11201900794PA (en) 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
EA039427B1 (ru) 2016-08-05 2022-01-26 Санофи Пастер Инк. Поливалентная пневмококковая полисахаридно-белковая конъюгатная композиция
KR102493853B1 (ko) 2016-08-19 2023-01-30 브리스톨-마이어스 스큅 컴퍼니 세코-시클로프로파피롤로인돌 화합물, 그의 항체-약물 접합체, 및 제조 및 사용 방법
EP3500594A4 (de) 2016-08-22 2020-03-11 Cho Pharma Inc. Antikörper, bindungsfragmente und verfahren zur verwendung
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
EP3305781A1 (de) 2016-10-07 2018-04-11 Deutsches Krebsforschungszentrum Chemische substanzen welche die enzymatische aktivität der humanen kallikrein-related peptidase 6 (klk6) hemmen.
MY191894A (en) 2016-10-13 2022-07-18 Nat Univ Singapore Antibodies that bind zika virus envelope protein and uses thereof
ES2908239T3 (es) 2016-10-28 2022-04-28 Astute Medical Inc Uso de anticuerpos contra timp-2 para la mejora de la función renal
WO2018085750A2 (en) 2016-11-07 2018-05-11 Bristol-Myers Squibb Company Immunomodulators
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US12049511B2 (en) 2016-11-10 2024-07-30 Fortis Therapeutics, Inc. Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
EP3538153B1 (de) 2016-11-11 2024-10-09 The Regents of the University of California Anti-cd46-antikörper und verfahren zur verwendung
CA3043131A1 (en) 2016-11-18 2018-05-24 Neurovive Pharmaceutical Ab Use of sanglifehrin macrocyclic analogues as anticancer compounds
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
JP2020502218A (ja) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
CN110325548B (zh) 2016-12-21 2023-11-17 美莱奥生物制药第三有限公司 抗硬化蛋白抗体在治疗成骨不全症中的用途
US10688244B2 (en) 2016-12-23 2020-06-23 Kaleo, Inc. Medicament delivery device and methods for delivering drugs to infants and children
IL308980A (en) 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods of their use
EP4371554A3 (de) 2016-12-31 2024-08-07 BioXcel Therapeutics, Inc. Verwendung von sublingualem dexmedetomidin zur behandlung von unruhe
HRP20230937T1 (hr) 2017-01-05 2023-11-24 Kahr Medical Ltd. Pd1-41bbl fuzijski protein i metode korištenja istog
HRP20220230T1 (hr) 2017-01-05 2022-04-29 Kahr Medical Ltd. Sirp1 alfa-41bbl fuzijski protein i metoda njegove upotrebe
US20180244785A1 (en) 2017-01-09 2018-08-30 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
US10332623B2 (en) 2017-01-17 2019-06-25 Kaleo, Inc. Medicament delivery devices with wireless connectivity and event detection
CN110312736B (zh) 2017-01-23 2023-05-09 苏州康宁杰瑞生物科技有限公司 Pd-l1结合多肽或化合物
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
GB2559553B (en) * 2017-02-06 2021-10-13 Consort Medical Plc A medicament delivery device
GB201702144D0 (en) 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
EP3576736A4 (de) 2017-02-10 2020-08-26 Torcept Therapeutics Inc. Rapamycinanalogon
KR102573778B1 (ko) 2017-02-17 2023-08-31 브리스톨-마이어스 스큅 컴퍼니 알파-시뉴클레인에 대한 항체 및 그의 용도
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
WO2018170336A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
MX2019011004A (es) 2017-03-15 2020-08-10 Modernatx Inc Compuestos y composiciones para la administracion intracelular de agentes terapeuticos.
EP3601326A4 (de) 2017-03-20 2020-12-16 The Broad Institute, Inc. Verbindungen und verfahren zur regulierung der insulinsekretion
USD867582S1 (en) 2017-03-24 2019-11-19 Allergan, Inc. Syringe device
SG11201909115WA (en) 2017-04-05 2019-10-30 Broad Inst Inc Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
CN110650976B (zh) 2017-04-13 2024-04-19 赛罗帕私人有限公司 抗SIRPα抗体
CN110573492A (zh) 2017-04-25 2019-12-13 阿米库斯治疗学公司 用于预防和/或治疗中枢神经系统退行性失调和/或溶酶体贮积失调的新颖组合物
MX2019013142A (es) 2017-05-05 2019-12-16 Amgen Inc Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion.
CA3063037A1 (en) 2017-05-10 2018-11-15 Albajuna Therapeutics, S.L. Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity
WO2018213097A1 (en) 2017-05-15 2018-11-22 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
MX2019013132A (es) 2017-05-25 2020-01-27 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
US12077501B2 (en) 2017-06-14 2024-09-03 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
BR112019027387A8 (pt) 2017-06-23 2022-12-06 Univ Maryland Composições imunogênicas
CA3068338A1 (en) 2017-06-23 2018-12-27 Suzhou Bojuhua Biomedical Technology Co. Ltd Monoclonal antibody targeting human tumor stem cells and use thereof
US11066445B2 (en) 2017-06-23 2021-07-20 Bristol-Myers Squibb Company Immunomodulators acting as antagonists of PD-1
WO2019013790A1 (en) 2017-07-12 2019-01-17 Curza Global, Llc ANTIMICROBIAL COMPOUNDS AND USES THEREOF
WO2019013789A1 (en) 2017-07-12 2019-01-17 Curza Global, Llc ANTIMICROBIAL COMPOUNDS
KR20200044066A (ko) 2017-08-22 2020-04-28 바이오젠 엠에이 인코포레이티드 항-알파(v)베타(6) 항체를 함유하는 약제학적 조성물 및 투약 요법
JP2020531041A (ja) 2017-08-28 2020-11-05 上海易楽生物技術有限公司 ポリペプチドとポリペプチドに結合される抗体
US11414450B1 (en) 2017-08-28 2022-08-16 Revagenix, Inc. Aminoglycosides and uses thereof
AU2018326799A1 (en) 2017-08-31 2020-02-27 Modernatx, Inc. Methods of making lipid nanoparticles
US11492375B2 (en) 2017-10-03 2022-11-08 Bristol-Myers Squibb Company Cyclic peptide immunomodulators
MX2020003549A (es) 2017-10-04 2020-08-03 Amgen Inc Fusiones de transtiretina e inmunoglobulina.
EP3694552A1 (de) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap-antikörper und verwendungen davon
MX2020003841A (es) 2017-10-11 2020-11-06 Greenlight Biosciences Inc Métodos y composiciones para la producción de nucleósido trifosfatos y ácidos ribonucleicos.
JP7035299B2 (ja) 2017-10-26 2022-03-15 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド 新規組換融合タンパク質、ならびにその調製および使用
EP3704159A1 (de) 2017-11-01 2020-09-09 Bristol-Myers Squibb Company Immunstimulatorische agonistische antikörper zur verwendung bei der krebsbehandlung
CR20200204A (es) 2017-11-17 2020-06-18 Merck Sharp & Dohme Anticuerpos especificos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos
US11786477B2 (en) 2017-12-01 2023-10-17 North Carolina State University Fibrin particles and methods of making the same
SG11202004273YA (en) 2017-12-11 2020-06-29 Amgen Inc Continuous manufacturing process for bispecific antibody products
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
WO2019126766A1 (en) * 2017-12-21 2019-06-27 Taiwan Liposome Co., Ltd. Sustained-release triptan compositions and method of use the same through subdermal route or the like
CA3083368A1 (en) 2017-12-21 2019-06-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
CA3083347A1 (en) 2017-12-21 2019-06-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
KR20200103761A (ko) 2017-12-27 2020-09-02 브리스톨-마이어스 스큅 컴퍼니 항-cd40 항체 및 그의 용도
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
CN111868082A (zh) 2018-02-02 2020-10-30 博奥泰克尼公司 调节vista和vsig3的相互作用的化合物及其制备和使用方法
KR101859735B1 (ko) 2018-02-07 2018-05-21 주식회사 피테크 무통 주사 장치
MA51747A (fr) 2018-02-08 2020-12-16 Amgen Inc Formulation d'anticorps pharmaceutique à ph faible
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
KR20200143391A (ko) 2018-03-15 2020-12-23 비온테크 알엔에이 파마슈티컬스 게엠베하 5'-캡-트리뉴클레오티드- 또는 고차의 올리고뉴클레오티드 화합물 및 이들의 rna 안정화, 단백질 발현 및 치료에서의 사용
TW202003565A (zh) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 抗mica及/或micb抗體及其用途
WO2019184920A1 (zh) 2018-03-26 2019-10-03 上海易乐生物技术有限公司 proBDNF调节剂在B细胞相关疾病中的用途
MX2020010204A (es) 2018-04-02 2021-01-29 Bristol Myers Squibb Co Anticuerpos anti-trem-1 y usos de los mismos.
US11673907B2 (en) 2018-04-03 2023-06-13 Revagenix, Inc. Modular synthesis of aminoglycosides
CA3096055A1 (en) 2018-04-06 2019-10-10 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
AU2019252795A1 (en) 2018-04-12 2020-10-29 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
BR112020021271A2 (pt) 2018-04-17 2021-01-26 Celldex Therapeutics, Inc. construtos bispecíficos e anticorpos anti- cd27 e anti-pd-l1
EP3781206A2 (de) 2018-04-20 2021-02-24 iOmx Therapeutics AG 5-thiazolcarboxamid-kinase-hemmer und verwendungen davon
KR102104080B1 (ko) * 2018-05-02 2020-04-23 주식회사 피테크 무통 주사기용 음파발진장치 및 이를 구비하는 무통 주사기
KR102107578B1 (ko) * 2018-05-02 2020-05-07 주식회사 피테크 무통 주사기용 약액주입 제어장치 및 이를 구비하는 무통 주사기
KR101907552B1 (ko) 2018-05-03 2018-10-12 주식회사 피테크 무바늘 무통 주사 장치
CA3096703A1 (en) 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
SG11202011667WA (en) 2018-05-25 2020-12-30 Primmune Therapeutics Inc Tlr7 agonists
CN112867394B (zh) 2018-06-04 2024-09-13 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体
US11951286B2 (en) * 2018-06-12 2024-04-09 Banza Stamping Industry Corp. Automatic injection device for fluid
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
MX2020014203A (es) 2018-06-21 2021-05-27 Yumanity Therapeutics Inc Composiciones y métodos para el tratamiento y la prevención de trastornos neurológicos.
SG11202012772XA (en) 2018-06-27 2021-01-28 Bioxcel Therapeutics Inc Film formulations containing dexmedetomidine and methods of producing them
WO2020012486A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
US11929160B2 (en) 2018-07-16 2024-03-12 Kaleo, Inc. Medicament delivery devices with wireless connectivity and compliance detection
JP2021532140A (ja) 2018-07-30 2021-11-25 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３３及びｃｄ３に結合する二重特異性抗体コンストラクトの長期投与
MX2021001085A (es) 2018-07-31 2021-03-31 Amgen Inc Formulaciones y composiciones farmaceuticas que comprenden una proteina de union a antigeno enmascarada.
AU2019316164A1 (en) 2018-07-31 2021-01-21 Amgen Inc. Dosing regimen for BCMA-CD3 bispecific antibodies
SG11202100987RA (en) 2018-08-03 2021-02-25 Amgen Res Munich Gmbh Antibody constructs for cldn18.2 and cd3
EP3833690B1 (de) 2018-08-08 2024-03-27 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Gegen cd47 und her2 gerichtetes, rekombinantes bifunktionales protein
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2020061210A1 (en) 2018-09-18 2020-03-26 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
WO2020061367A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
KR102199724B1 (ko) * 2018-10-05 2021-01-07 주식회사 피테크 무바늘 무통 주사 장치
US11130802B2 (en) 2018-10-10 2021-09-28 Tilos Therapeutics, Inc. Anti-lap antibody variants
CA3114802A1 (en) 2018-10-11 2020-04-16 Amgen Inc. Downstream processing of bispecific antibody constructs
US20220024944A1 (en) 2018-10-23 2022-01-27 Myelopro Diagnostics And Research Gmbh Compounds targeting mutant calreticulin
EP3643713A1 (de) 2018-10-23 2020-04-29 iOmx Therapeutics AG Heterocyclische kinasehemmer und verwendungen davon
US11160791B2 (en) 2018-11-01 2021-11-02 Medefil, Inc. Dexmedetomidine injection premix formulation in ready to use (RTU) bags
EP4257195A3 (de) 2018-11-09 2024-01-03 University of Massachusetts Anti-cfae-antikörper und verfahren zur verwendung
WO2020102501A1 (en) 2018-11-16 2020-05-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof
JP2022513653A (ja) 2018-11-28 2022-02-09 ブリストル－マイヤーズ スクイブ カンパニー 修飾された重鎖定常領域を含む抗体
WO2020118011A1 (en) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
CN113195532A (zh) 2018-12-18 2021-07-30 瑞泽恩制药公司 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法
WO2020128863A1 (en) 2018-12-19 2020-06-25 Novartis Ag Anti-tnf-alpha antibodies
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
WO2020144535A1 (en) 2019-01-08 2020-07-16 Aduro Biotech Holdings, Europe B.V. Methods and compositions for treatment of multiple myeloma
US20230072397A1 (en) 2019-01-16 2023-03-09 Curza Global, Llc Antimicrobial Compounds and Methods
US20230159491A1 (en) 2019-01-16 2023-05-25 Curza Global, Llc Antimicrobial Compounds and Methods
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
WO2020154293A1 (en) 2019-01-22 2020-07-30 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
EP3914291A2 (de) 2019-01-22 2021-12-01 F. Hoffmann-La Roche AG Immunoglobulin-a-antikörper und verfahren zur herstellung und verwendung
EA202191983A1 (ru) 2019-01-22 2021-12-01 Аеовиан Фармасьютикалз, Инк. МОДУЛЯТОРЫ mTORC И ИХ ПРИМЕНЕНИЕ
KR20210135494A (ko) 2019-01-31 2021-11-15 모더나티엑스, 인크. 지질 나노입자의 제조 방법
WO2020168466A1 (en) 2019-02-19 2020-08-27 Stemirna Therapeutics Co., Ltd. Modified nucleoside and synthetic methods thereof
CA3131953A1 (en) 2019-03-01 2020-09-10 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
UY38605A (es) 2019-03-11 2020-09-30 Biogen Ma Inc Composiciones farmacéuticas que contienen anticuerpos anti-lingo-1
EP3946613A1 (de) 2019-03-25 2022-02-09 Visterra, Inc. Zusammensetzungen und verfahren zur behandlung und vorbeugung von grippe
EA202192400A1 (ru) 2019-04-08 2022-01-25 Биоген Ма Инк. Антитела против интегрина и их применение
EP3972694A1 (de) 2019-05-21 2022-03-30 Bristol-Myers Squibb Company Immunmodulatoren
KR20220019755A (ko) 2019-06-11 2022-02-17 리제너론 파마슈티칼스 인코포레이티드 PcrV에 결합하는 항-PcrV 항체, 항-PcrV 항체를 포함하는 조성물, 및 이의 사용 방법
US20220259547A1 (en) 2019-06-13 2022-08-18 Amgeng Inc. Automated biomass-based perfusion control in the manufacturing of biologics
US20220324924A1 (en) 2019-07-08 2022-10-13 Amgen Inc. Multispecific transthyretin immunoglobulin fusions
JP2022541742A (ja) 2019-07-11 2022-09-27 カール メディカル リミテッド ヘテロダイマーおよびその使用方法
WO2021011681A1 (en) 2019-07-15 2021-01-21 Bristol-Myers Squibb Company Antibodies against human trem-1 and uses thereof
AU2020312686A1 (en) 2019-07-15 2022-02-03 Intervet International B.V. Caninized antibodies against canine CTLA-4
WO2021009188A1 (en) 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies to human and canine ctla-4
WO2021011678A1 (en) 2019-07-15 2021-01-21 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
WO2021016112A2 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
EP4003296A1 (de) 2019-07-31 2022-06-01 ModernaTX, Inc. Zusammensetzungen und verfahren zur abgabe von rna-interferenzmitteln an immunzellen
MX2022001241A (es) 2019-07-31 2022-04-20 Sanofi Pasteur Inc Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos.
US11167087B2 (en) 2019-08-09 2021-11-09 Kaleo, Inc. Devices and methods for delivery of substances within a prefilled syringe
AR119769A1 (es) 2019-08-13 2022-01-12 Amgen Inc Muteínas de interleucina-2 para la expansión de células t reguladoras
JP2022547305A (ja) 2019-09-13 2022-11-11 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー Ａａｖ適合性ラミニン－リンカー重合タンパク質
KR20220088868A (ko) 2019-10-30 2022-06-28 브리스톨-마이어스 스큅 컴퍼니 면역조정제
FI3819007T3 (fi) 2019-11-11 2024-09-25 Amgen Res Munich Gmbh Annosteluohjelma anti-bcma-aineille
AU2020381536A1 (en) 2019-11-13 2022-04-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
US20230278987A1 (en) 2019-11-13 2023-09-07 Curza Global, Llc Antimicrobial Compounds and Methods
US20230022400A1 (en) 2019-11-19 2023-01-26 Bristol-Myers Squibb Company Immunomodulators
IL293804A (en) 2019-12-11 2022-08-01 Visterra Inc Anti-hemagglutinin (ha) antibody molecules, preparations containing them and their uses
AU2020407208A1 (en) 2019-12-17 2022-06-02 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
IL293640A (en) 2019-12-20 2022-08-01 Amgen Inc CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
AU2020407853A1 (en) 2019-12-20 2022-06-09 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
WO2021123094A1 (en) 2019-12-20 2021-06-24 Intervet International B.V. Bispecific caninized antibodies and bispecific binding partners for treating atopic dermatitis
CN114929728A (zh) 2020-01-06 2022-08-19 百时美施贵宝公司 免疫调节剂
KR20220122751A (ko) 2020-01-06 2022-09-02 브리스톨-마이어스 스큅 컴퍼니 암 및 감염성 질환의 치료를 위한 pd-l1 억제제 및 면역조정제로서의 마크로시클릭 펩티드
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
CN116133652A (zh) 2020-01-31 2023-05-16 摩登纳特斯有限公司 制备脂质纳米粒子的方法
WO2021170020A1 (en) 2020-02-27 2021-09-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibodies binding il4r and uses thereof
US11642407B2 (en) 2020-02-28 2023-05-09 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
US20230140384A1 (en) 2020-03-09 2023-05-04 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
KR20220155332A (ko) 2020-03-16 2022-11-22 브리스톨-마이어스 스큅 컴퍼니 면역조정제
EP4121459A1 (de) 2020-03-19 2023-01-25 Amgen Inc. Antikörper gegen mucin 17 und verwendungen davon
WO2021195089A1 (en) 2020-03-23 2021-09-30 Sorrento Therapeutics, Inc. Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
EP4126902B1 (de) 2020-03-30 2023-12-06 Bristol-Myers Squibb Company Immunmodulatoren
US20230107644A1 (en) 2020-04-01 2023-04-06 University Of Rochester Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
EP4132971A1 (de) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinitätsgereifte anti-lap-antikörper und verwendungen davon
EP3901151A1 (de) 2020-04-21 2021-10-27 iOmx Therapeutics AG Halogenierte heteroaryl- und andere heterocyclische kinaseinhibitoren und verwendungen davon
WO2021216488A1 (en) 2020-04-21 2021-10-28 Regeneron Pharmaceuticals, Inc. Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof
US20230192701A1 (en) 2020-04-28 2023-06-22 Iomx Therapeutics Ag Bicyclic kinase inhibitors and uses thereof
MX2021015024A (es) 2020-04-28 2022-01-18 Univ Rockefeller Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
CN115484980A (zh) 2020-04-29 2022-12-16 安进公司 药物配制品
CN115461080A (zh) 2020-04-29 2022-12-09 安进公司 药物配制品
AU2021265205A1 (en) 2020-04-30 2023-01-05 Academisch Ziekenhuis Groningen Anti-CD103 antibodies
KR20230008790A (ko) 2020-05-08 2023-01-16 브리스톨-마이어스 스큅 컴퍼니 면역조정제
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
JP2023527293A (ja) 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
CN111529830B (zh) * 2020-05-22 2024-10-15 江阴市机电技术有限公司 一种启动稳定的给药装置
US20230277524A1 (en) 2020-05-22 2023-09-07 Trailhead Biosystems Inc. Combination therapy for treatment of viral infections
WO2021243320A2 (en) 2020-05-29 2021-12-02 Amgen Inc. Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3
US20240148889A1 (en) 2020-06-11 2024-05-09 President And Fellows Of Harvard College Stabilized trioxacarcin antibody drug conjugates and uses thereof
FR3112939B1 (fr) 2020-07-31 2024-01-05 Univ Montpellier Produit universel de thérapie cellulaire et son utilisation
CN116419747A (zh) 2020-08-07 2023-07-11 福蒂斯治疗公司 靶向cd46的免疫偶联物及其使用方法
JP2023538669A (ja) 2020-08-24 2023-09-08 アムジェン インコーポレイテッド Ｂｉｔｅ、二重特異性抗体、及びメチオニンを含む医薬製剤
KR20230079150A (ko) 2020-10-02 2023-06-05 브리스톨-마이어스 스큅 컴퍼니 마크로시클릭 펩티드 보로네이트 면역조정제
KR20230084209A (ko) 2020-10-08 2023-06-12 브리스톨-마이어스 스큅 컴퍼니 이량체 밀라 면역조정제
WO2022076796A1 (en) 2020-10-09 2022-04-14 Bristol-Myers Squibb Company Macrocyclic immunomodulators
MX2023004438A (es) 2020-10-15 2023-05-08 Intervet Int Bv Anticuerpos de rata caninizados para el receptor alfa de interleucina-31 canino.
WO2022092295A1 (ja) 2020-10-30 2022-05-05 Ｘｅｎｏ－Ｉｎｔｅｒｆａｃｅ株式会社 βストランド型架橋ペプチド
EP4238567A4 (de) 2020-10-30 2024-09-04 Univ Keio Neuartige behandlung und prävention von erkrankungen im zusammenhang mit sarkopenie
TW202227481A (zh) 2020-11-04 2022-07-16 美國洛克菲勒大學 中和抗sars-cov-2抗體
AU2021374036A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
BR112023008670A2 (pt) 2020-11-06 2024-02-06 Amgen Inc Construtos polipeptídicos ligados à cd3
CN116323671A (zh) 2020-11-06 2023-06-23 安进公司 具有增加的选择性的多靶向性双特异性抗原结合分子
JP2023548345A (ja) 2020-11-06 2023-11-16 アムジエン・インコーポレーテツド クリッピング率の低減した抗原結合ドメイン
WO2022103781A1 (en) 2020-11-10 2022-05-19 Amgen Inc. Methods for administering a bcma x cd3 binding molecule
CN116547305A (zh) 2020-11-11 2023-08-04 生物技术公司 针对程序性死亡-1蛋白的单克隆抗体及其在医学中的用途
AR124267A1 (es) 2020-12-09 2023-03-01 Genentech Inc Métodos de alto rendimiento para preparar nanopartículas lipídicas y sus usos
DE102020134181A1 (de) 2020-12-18 2022-06-23 Henke-Sass, Wolf Gmbh Vorrichtung zum Applizieren eines Fluids
CN114685669A (zh) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
US12060411B2 (en) 2021-01-15 2024-08-13 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
EP4305088A1 (de) 2021-03-09 2024-01-17 Massachusetts Institute of Technology Verzweigte poly(aminoester) zur verabreichung von nukleinsäuren
BR112023017661A2 (pt) 2021-03-12 2023-12-05 Bristol Myers Squibb Co Inibidores de kras
WO2022204412A1 (en) 2021-03-24 2022-09-29 Bristol-Myers Squibb Company Immunomodulators
AU2022253269A1 (en) 2021-04-09 2023-11-23 Celldex Therapeutics, Inc. Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
JP2024516369A (ja) 2021-04-12 2024-04-15 ブリストル－マイヤーズ スクイブ カンパニー 環状ペプチド免疫調節剤
WO2022234102A1 (en) 2021-05-06 2022-11-10 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
US20240207354A1 (en) 2021-05-06 2024-06-27 Amgen Inc. Etelcalcetide formulations
EP4334343A2 (de) 2021-05-06 2024-03-13 The Rockefeller University Neutralisierende anti-sars-cov-2-antikörper und verfahren zur verwendung davon
EP4337197A1 (de) 2021-05-10 2024-03-20 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Pharmazeutische zusammensetzungen zur behandlung neurologischer erkrankungen
EP4346882A1 (de) 2021-05-26 2024-04-10 Oxford BioTherapeutics Ltd Pharmazeutische kombination mit einem anti-cd205-antikörper und einem immun-checkpoint-inhibitor
TW202313065A (zh) 2021-05-28 2023-04-01 美商季卡尼醫療公司 用於治療遺傳疾病之化合物
JP2024527473A (ja) 2021-06-09 2024-07-25 ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー 新規な抗線維化薬
CN117425666A (zh) 2021-06-09 2024-01-19 百时美施贵宝公司 环肽免疫调节剂
IL308847A (en) 2021-06-30 2024-01-01 Amgen Inc The method of recovering a freeze-dried formulation
CN118076623A (zh) 2021-07-12 2024-05-24 百时美施贵宝公司 大环免疫调节剂
EP4373835A1 (de) 2021-07-19 2024-05-29 Bristol-Myers Squibb Company Makrocyclische immunmodulatoren
AU2022316209A1 (en) 2021-07-20 2024-02-22 Regeneron Pharmaceuticals, Inc. Butyrophilin-like 2 agents for treating inflammatory disorders
CN113398365B (zh) * 2021-07-21 2022-10-28 南京瑞淇卓越医疗美容诊所有限公司 一种心血管内科用的临床造影注射装置及注射方法
EP4384534A1 (de) 2021-08-11 2024-06-19 Sanofi Pasteur, Inc. Verkürzte influenza-neuraminidase und verfahren zur verwendung davon
WO2023021170A2 (en) 2021-08-20 2023-02-23 Intervet International B.V. Fusion proteins for treating atopic dermatitis
JP2024531346A (ja) 2021-08-20 2024-08-29 インターベット インターナショナル ベー． フェー． 半減期が延長された抗体およびＩｇＧ融合タンパク質
WO2023039108A1 (en) 2021-09-08 2023-03-16 Affinivax, Inc. Coronavirus vaccine
CN113773401B (zh) 2021-09-15 2023-06-20 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和pd-l1的重组融合蛋白及其制备和用途
JP2024537180A (ja) 2021-10-08 2024-10-10 サノフィ パスツール インコーポレイテッド 多価インフルエンザワクチン
CN113831412B (zh) 2021-10-13 2023-06-20 宜明昂科生物医药技术（上海）股份有限公司 靶向cd24的抗体及其制备和用途
CN113956363B (zh) 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
CN113754769B (zh) 2021-10-13 2023-06-06 宜明昂科生物医药技术（上海）股份有限公司 靶向cd70的抗体及其制备和用途
AU2022364888A1 (en) 2021-10-14 2024-05-30 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
CN118159549A (zh) 2021-10-20 2024-06-07 百时美施贵宝公司 免疫调节剂
KR20240099382A (ko) 2021-11-03 2024-06-28 아피메트 게엠베하 이중특이적 cd16a 결합제
EP4426433A1 (de) 2021-11-03 2024-09-11 Affimed GmbH Bispezifische cd16a-bindemittel
IL312502A (en) 2021-11-05 2024-07-01 Sanofi Sa Hybrid multivalent influenza vaccines containing hemagglutinin and neuraminidase and methods of using them
IL312545A (en) 2021-11-05 2024-07-01 Sanofi Pasteur Inc Multivalent Influenza Vaccines Including Hemagglutinin and Recombinant Neuraminidase and Methods of Using Them
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
EP4433170A1 (de) 2021-11-18 2024-09-25 Oxford BioTherapeutics Ltd Pharmazeutische kombinationen
WO2023096904A2 (en) 2021-11-24 2023-06-01 President And Fellows Of Harvard College C-16 modified trioxacarcins, antibody drug conjugates, and uses thereof
WO2023102507A1 (en) 2021-12-03 2023-06-08 Bristol-Myers Squibb Company Macrocyclic immunomodulators
WO2023105281A1 (en) 2021-12-11 2023-06-15 Fundaciò Privada Institut De Recerca De La Sida-Caixa Soluble tigit recombinant proteins
WO2023114884A2 (en) 2021-12-15 2023-06-22 Interius Biotherapeutics, Inc. Pseudotyped viral particles, compositions comprising the same, and uses thereof
MX2024007090A (es) 2021-12-16 2024-08-22 Intervet Int B V Anticuerpos caninizados para el receptor alfa ii de interleucina-31 canino.
WO2023111157A1 (en) 2021-12-16 2023-06-22 Intervet International B.V. Caninized and felinized antibodies to human ngf
WO2023114889A1 (en) 2021-12-16 2023-06-22 Modernatx, Inc. Processes for preparing lipid nanoparticles
AU2022411573A1 (en) 2021-12-17 2024-06-27 Shanghai Henlius Biologics Co., Ltd. Anti-ox40 antibodies and methods of use
EP4448578A1 (de) 2021-12-17 2024-10-23 Shanghai Henlius Biotech, Inc. Anti-ox40-antikörper, multispezifische antikörper und verfahren zur verwendung
CA3240195A1 (en) 2021-12-30 2023-07-06 Paul R. Sebahar Antimicrobial compounds and methods
WO2023145735A1 (ja) 2022-01-25 2023-08-03 元詞 早野 サルコペニアを含む老化関連異常の抑制の新規治療と予防
WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
WO2023144206A1 (en) 2022-01-27 2023-08-03 Sanofi Pasteur Modified vero cells and methods of using the same for virus production
AU2023228405A1 (en) 2022-03-04 2024-10-10 Revagenix, Inc. Broad spectrum aminoglycosides and uses thereof
WO2023177579A1 (en) 2022-03-14 2023-09-21 Sanofi Pasteur Inc. Machine-learning techniques in protein design for vaccine generation
WO2023175171A1 (en) 2022-03-18 2023-09-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Bk polyomavirus antibodies and uses thereof
WO2023179740A1 (en) 2022-03-25 2023-09-28 Shanghai Henlius Biotech , Inc. Anti-msln antibodies and methods of use
WO2023192873A1 (en) 2022-03-28 2023-10-05 Bristol-Myers Squibb Company Macrocyclic immunomodulators
WO2023193002A1 (en) 2022-04-01 2023-10-05 Modernatx, Inc. Cross mixers for lipid nanoparticle production, and methods of operating the same
EP4257132A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3-inhibitoren zum behandeln von krankheiten, die gegen death-rezeptor -signaltransduktion resistent sind
EP4257609A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Kombinationstherapien basierend auf pd-1-inhibitoren und sik3-inhibitoren
WO2023212559A1 (en) 2022-04-26 2023-11-02 Amgen Inc. Lyophilization method
TW202346368A (zh) 2022-05-12 2023-12-01 德商安美基研究（慕尼黑）公司 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
WO2023217987A1 (en) 2022-05-12 2023-11-16 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
GB202207263D0 (en) 2022-05-18 2022-06-29 Annexin Pharmaceuticals Ab Therapeutic compositions
WO2023225661A1 (en) 2022-05-20 2023-11-23 Bristol-Myers Squibb Company Macrocyclic immunomodulators
WO2023235380A1 (en) 2022-06-01 2023-12-07 Zikani Therapeutics, Inc. Macrolides for treating genetic diseases
WO2023240189A1 (en) 2022-06-10 2023-12-14 Bristol-Myers Squibb Company Tetrahydropyrido 3,4-d pyrimidine derivatives as kras inhibitors
WO2023240188A1 (en) 2022-06-10 2023-12-14 Bristol-Myers Squibb Company Pyrido[4,3-d]pyrimidine derivatives as kras inhibitors
WO2023250513A1 (en) 2022-06-24 2023-12-28 Zikani Therapeutics, Inc. 13-membered macrolide compounds for treating diseases mediated by abnormal protein translation
WO2024026475A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses
WO2024026482A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Lipid nanoparticle compositions comprising surface lipid derivatives and related uses
WO2024026487A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Lipid nanoparticle compositions comprising phospholipid derivatives and related uses
WO2024036270A1 (en) 2022-08-11 2024-02-15 Bristol-Myers Squibb Company Kras inhibitors
WO2024040109A2 (en) 2022-08-16 2024-02-22 Bristol-Myers Squibb Company Kras inhibitors
WO2024049994A1 (en) 2022-09-01 2024-03-07 Zikani Therapeutics, Inc. Treatment of familial adenomatous polyopsis using a 13-membered macrolide
WO2024054926A1 (en) 2022-09-07 2024-03-14 Bristol-Myers Squibb Company Kras g12d inhibitors
WO2024059472A1 (en) 2022-09-12 2024-03-21 Bristol-Myers Squibb Company Macrocyclic immunomodulators
TW202421650A (zh) 2022-09-14 2024-06-01 美商安進公司 雙特異性分子穩定組成物
WO2024091918A2 (en) 2022-10-25 2024-05-02 Modernatx, Inc. Methods of lipid nanoparticle production in cross-mixers
TW202426490A (zh) 2022-11-21 2024-07-01 美商黛安瑟斯醫療運營公司 結合ｃ１ｓ之抗體及其用途
CN115737992B (zh) * 2022-11-24 2024-06-07 深圳市本尚医疗科技有限公司 无针注射器
WO2024115713A1 (en) 2022-11-30 2024-06-06 The Trustees Of The University Of Pennsylvania Brisc deubiquitinating enzyme inhibitors
WO2024121380A1 (en) 2022-12-08 2024-06-13 Pierre Fabre Medicament Vaccinal composition and adjuvant
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024170486A1 (en) 2023-02-13 2024-08-22 Intervet International B.V. Canine antibodies to canine il-4
WO2024170485A1 (en) 2023-02-13 2024-08-22 Intervet International B.V. Canine antibodies to canine il-13
WO2024186635A2 (en) 2023-03-03 2024-09-12 Celldex Therapeutics, Inc. Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
WO2024187062A1 (en) 2023-03-08 2024-09-12 Amgen Inc. Controlled-ice nucleation lyophilization process for bispecific molecules
WO2024188356A1 (en) 2023-03-16 2024-09-19 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Ilt7-targeting antibodies and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2704543A (en) * 1955-03-22 Hypo jet injector
US2101140A (en) * 1935-03-23 1937-12-07 Raymond W Hege Automatic injecting syringe device
US2380534A (en) * 1941-04-26 1945-07-31 Marshall L Lockhart Hypodermic injector
US2605763A (en) * 1948-01-31 1952-08-05 Becton Dickinson Co Injection device
US2547099A (en) * 1948-03-11 1951-04-03 Becton Dickinson Co Injection device and ampoule
US2680439A (en) * 1948-09-08 1954-06-08 Arnold K Sutermeister High-pressure injection device
US2670121A (en) * 1951-01-31 1954-02-23 Scherer Corp R P Flexible follower for metal ampoules
US2816543A (en) * 1954-07-12 1957-12-17 Scherer Corp R P Hypodermic injector
DE1287743B (de) * 1960-08-15 1969-01-23
US3292621A (en) * 1963-07-19 1966-12-20 Oscar H Banker Jet type protable inoculator
US3292622A (en) * 1964-09-21 1966-12-20 Oscar H Banker Power operated inoculator
US3424154A (en) * 1965-11-08 1969-01-28 Charles W Kinsley Injection system
US3561443A (en) * 1968-09-06 1971-02-09 Oscar H Banker Inoculator gun with delayed action
US3688765A (en) * 1969-10-03 1972-09-05 Jack S Gasaway Hypodermic injection device
US3945379A (en) * 1974-08-08 1976-03-23 Smithkline Corporation Injection device
JPS51130094A (en) * 1975-05-08 1976-11-12 Asahi Chemical Ind Twoostage pressure injector
CA1178503A (en) * 1982-05-27 1984-11-27 Health-Mor Personal Care Corporation Needleless hypodermic injector
HU186718B (en) * 1983-06-29 1985-09-30 Radelkis Electrokemiai Automatic needleless syringe operable by cardox cylinder suitable for personal giving injection e.g. insulin
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4680027A (en) * 1985-12-12 1987-07-14 Injet Medical Products, Inc. Needleless hypodermic injection device
EP0250022A3 (de) * 1986-06-17 1988-06-22 SICIM SpA Tragbarer hypodermatischer Injektor
US4722728A (en) * 1987-01-23 1988-02-02 Patents Unlimited, Ltd. Needleless hypodermic injector
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) * 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
DE3814023A1 (de) * 1987-07-13 1989-01-26 Medizin Labortechnik Veb K Injektionsvorrichtung mit medikamentendepot
US5009637A (en) * 1987-11-16 1991-04-23 Sy-Quest International Limited Apparatus for hypodermic injection of liquids
US5073165A (en) * 1988-02-05 1991-12-17 Marpam International, Inc. Hypodermic jet injector and cartridge therefor
US4913699A (en) * 1988-03-14 1990-04-03 Parsons James S Disposable needleless injection system
US5024656A (en) * 1988-08-30 1991-06-18 Injet Medical Products, Inc. Gas-pressure-regulated needleless injection system
CA1325149C (en) * 1989-08-31 1993-12-14 Gavin Mcgregor Variable intensity remote controlled needleless injector
US5064413A (en) * 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5062830A (en) * 1990-04-04 1991-11-05 Derata Corporation Dry disposable nozzle assembly for medical jet injector
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43824E1 (en) 2001-01-11 2012-11-20 Powder Pharmaceuticals Inc. Needleless syringe
US8540665B2 (en) 2007-05-04 2013-09-24 Powder Pharmaceuticals Inc. Particle cassettes and processes therefor
US9044546B2 (en) 2007-05-04 2015-06-02 Powder Pharmaceuticals Incorporated Particle cassettes and processes therefor
US9358338B2 (en) 2007-05-04 2016-06-07 Powder Pharmaceuticals Incorporated Particle cassettes and processes therefor

Also Published As

Publication number Publication date
US5399163A (en) 1995-03-21
EP0651663A4 (de) 1995-08-30
AU4782793A (en) 1994-02-14
JP3633615B2 (ja) 2005-03-30
US5383851A (en) 1995-01-24
EP0651663A1 (de) 1995-05-10
WO1994002188A1 (en) 1994-02-03
CA2140772A1 (en) 1994-02-03
JP2004141667A (ja) 2004-05-20
US5520639A (en) 1996-05-28
JPH07509161A (ja) 1995-10-12
ATE187083T1 (de) 1999-12-15
DE69327165D1 (de) 2000-01-05
DE69327165T2 (de) 2000-08-24
AU676490B2 (en) 1997-03-13
CA2140772C (en) 2006-07-11

Similar Documents

Publication Publication Date Title
EP0651663B1 (de) Verfahren für nadellose subkutaninjektionen
WO1994002188A9 (en) Needleless hypodermic injection methods and device
US10918791B2 (en) Devices, systems and methods for medicament delivery
EP0427457B1 (de) Ampulle für nadelloses, hypodermisches Injektionsgerät
US6939319B1 (en) Process and device for single use, needle-free intradermal, subcutaneous, or intramuscular injections
US8361029B2 (en) Devices, systems and methods for medicament delivery
US5312335A (en) Needleless hypodermic injection device
US4194505A (en) Containerized hypodermic module
US5049125A (en) Needleless injection apparatus of a liquid, notably for dental care
CA2476076C (en) Injector with bypass channel
US5024656A (en) Gas-pressure-regulated needleless injection system
AU675534B2 (en) Multiple medication injection apparatus and method
WO2004101025A2 (en) Needle free hypodermic injector and ampule for intradermal, subcutaneous and intramuscular injection
US20020099329A1 (en) Gas power sources for needle-less injector and needle-less injectors incorporating the same
WO1992021395A1 (en) Auto-retracting needle injector system
GB2143737A (en) Needleless injector
JP2003529417A (ja) １回限り使用の使い捨て型ジェット注射器

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19980507

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19991201

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991201

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991201

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 19991201

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991201

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19991201

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991201

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991201

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991201

REF Corresponds to:

Ref document number: 187083

Country of ref document: AT

Date of ref document: 19991215

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69327165

Country of ref document: DE

Date of ref document: 20000105

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000302

ET Fr: translation filed
NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000723

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 20000731

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20120723

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20120809

Year of fee payment: 20

Ref country code: DE

Payment date: 20120731

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69327165

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20130722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130724

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130722